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The development of modern cancer therapies and newer multimodality therapies 
has led to increased survival in most early onset cancer patients. As more patients 
experience long-term survival, the late effects of cancer and its treatments affecting 
both the health and quality of life of survivors have become evident. Female cancer 
survivors are concerned about the possible adverse effects of cancer and its 
treatment on their reproductive health. The aim of this study was to evaluate the use 
of fertility treatments, as well as the risk of adverse pregnancy-related conditions and 
obstetric outcomes, in female early onset cancer survivors. 
 
In this thesis, Finnish population-based registers were used to compare female 
cancer survivors to female siblings (Studies I, II and IV) and age-matched female 
comparison subjects (Study III). The study cohort, which was identified from the 
Finnish Cancer Registry, comprised female cancer survivors diagnosed with cancer 
between 1953 and 2004 at the age of 0-34 years (N=13,799) and between 1953 and 
2012 at the age of 0-39 years (N=24,610). Female siblings and age-matched 
comparison subjects were identified by linkage to the Central Population Register. 
Information on the use of fertility drugs (Study I) was obtained from the 
Reimbursement Register of Prescribed Medicines. Information on fertility 
treatments in women giving birth (Study II), as well as information on pregnancy-
related conditions (Study III) and obstetric outcomes (Study IV), was retrieved from 
the Medical Birth Register.  
 
In Study I, we used Poisson regression modelling to estimate incidence rate ratios 
(IRRs) for the use of fertility drugs, adjusting for attained age and calendar time at 
fertility drug purchase. In Studies II, III and IV, we used logistic regression modelling 
to calculate odds ratios (ORs) for fertility treatments, pregnancy-related conditions 
and obstetric outcomes. 
 
We found an increased use of fertility drugs in female cancer survivors between 
1993 and 2012 compared to siblings (IRR 1.43, 95% confidence interval [CI] 1.25-
1.65), which could be explained by the increased use of assisted reproductive 
technology (IRR 2.41, 95% CI 1.97-2.96). Time period played a key role, with 
increased use of fertility treatments and assisted reproductive technology in cancer 
survivors from 2003 onwards (Study I). Female cancer survivors giving birth between 
2004 and 2013 had an increased use of fertility treatments compared to siblings (OR 
1.84, 95% CI 1.18-2.86) (Study II). Survivors, diagnosed in their childhood, had the 
lowest use of fertility treatments and seemed to become pregnant with less 
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extensive fertility treatments than survivors diagnosed as young adults. In cancer 
survivors giving birth, time elapsed from cancer treatment increased the use of 
fertility treatments over time, suggesting that cancer treatments lead to a diminished 
ovarian reserve and a narrowed fertile window (Study II). 
 
One aim for this thesis was to explore the underlying reasons for the previously 
reported increased risk of preterm delivery. Our results showed that vaginal bleeding 
and pre-eclampsia might be more severe in cancer survivors, as survivors with these 
conditions had a 35% higher risk for preterm delivery compared to comparison 
subjects with the same conditions (Study III). In addition, cancer survivors had an 
overall increased risk for hospitalization during pregnancy (OR 1.45, 95% CI 1.25-
1.68), intrahepatic cholestasis (OR 2.86, 95% CI 1.09-7.49) fear of childbirth (OR 2.25, 
95% CI 1.31-3.85) and mental disorders and diseases of the nervous system (OR 5.89, 
95% CI 2.31-15.00) (Study III). Cancer survivors also had an increased risk for 
induction of labor (OR 1.17, 95% CI 1.02-1.35) and elective cesarean sections (OR 
1.36, 95% CI 1.11-1.67) compared to siblings. The risk for adverse obstetric outcomes 
was most increased in childhood cancer survivors (Study IV).  
 
The increased use of fertility treatments in female cancer survivors emphasizes 
the need for collaboration between oncologists and gynecologists in order to identify 
those cancer survivors at risk for subfertility or infertility. Our results show an 
increased use of fertility treatments during recent years, indicating a more active 
approach towards treating cancer survivors with fertility issues. Our results further 
indicate that once pregnant, though most cancer survivors have uncomplicated 
deliveries, some are at an elevated risk for complications, that place them at risk of 
preterm delivery and adverse obstetric outcomes. Health-care providers should be 
aware of these risks, attempt to identify these women and provide adequate follow 
up for this subgroup.  
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According to registry data from recent years, 166 children under the age of 15 years 
and 1,144 adolescents and young adults, aged 15 to 39 years, are diagnosed with 
cancer every year (Finnish Cancer Registry Statistics 2012-2016). Fortunately, 
advances in diagnostics and treatment combinations over the last decades have led 
to a greater chance of long-term survival for cancer patients than ever before. The 
five-year survival rate for children diagnosed with cancer in Finland during 2000-2010 
was 81% according to a recent study (Madanat-Harjuoja et al. 2014). For adolescents 
and young adults in Europe, the five-year survival rate was as high as 82% during 
2005-2007 (Trama et al. 2016).  
 
However, the same treatments that have led to survival and cure, will lead to 
adverse health conditions in at least two out of three cancer survivors later in life 
(Oeffinger et al. 2006). These chronic health conditions can be organ specific, 
cognitive or hormonal (Hudson et al. 2013). Already in 1975 Giulio D’Angio, a pioneer 
in the treatment of childhood cancers, was concerned about the possible late effects 
after cancer treatments (D’Angio et al. 1975). Awareness of these late effects led to 
an effort to modify and modernize cancer treatments to diminish late complications 
(Hudson et al. 2011). Recently, effort has also been made to inform health-care 
providers and cancer survivors about the late effects, to allow early recognition and 
treatment, and to employ prevention strategies when possible (Hjort et al. 2018, 
Haupt et al. 2018). A recent development is the Survivorship passport (Surpass), an 
electronic document that includes a summary of each survivor's clinical history. The 
Surpass includes information on the primary cancer, received treatments and 
personalized follow-up and screening recommendations based on the European 
guidelines (Haupt et al. 2018). 
 
Among cancer survivors, infertility is one of the major concerns and it often leads 
to distress and interference with intimate relationships thus influencing quality of life 
(Peate et al. 2009 and Gilleland et al. 2015). Overall, the prevalence of infertility is 
increasing worldwide and is now estimated to be 12.5-16% of the Western 
population (Terävä et al. 2008 and Datta et al. 2016). One contributing factor to this 
increase is believed to be the use of gonadotoxic treatments in cancer patients 
(Petraglia et al. 2013). As more women postpone childbirth and the number of cancer 
survivors continues to rise, there is an increasing number of women who desire 




Many studies have demonstrated reduced probability of pregnancy and 
parenthood in cancer survivors (Madanat et al. 2008, Green et al 2009, Anderson et 
al 2018). However, only a few studies have been published regarding infertility 
rates and fertility treatments among cancer survivors (Das et al. 2012, Barton et al. 
2013, Luke et al 2016). An American study found that cancer survivors were as 
likely as their siblings to seek medical help for infertility but less likely to be 
prescribed fertility drugs (Barton et al 2013). The study did not offer explanations 
for why reproductive medicine providers prescribed fewer fertility drugs to cancer 
survivors, indicating a need for more studies on fertility treatments among cancer 
survivors. 
 
Once pregnant, previous studies have shown that cancer survivors have an 
increased risk for preterm delivery (Signorello et al. 2006, Madanat-Harjuoja et al. 
2010, van der Kooi et al. 2018). The mechanisms underlying this increased risk, 
however, are unclear. Studies have shown that female survivors who received 
abdominal radiotherapy have a higher risk for preterm delivery compared to female 
controls (Green et al. 2010). Reduced vascular supply and uterine fibrosis due to 
radiotherapy could lead to premature contractions and spontaneous preterm 
delivery (Critchley et al. 1999). Another explanation could be maternal pregnancy-
related conditions that are known to necessitate medically induced preterm 
delivery. The most common conditions include pre-eclampsia, gestational diabetes 
and placental pathologies (Ananth et al. 2006). We know that cancer treatments 
can lead to cardiovascular late effects (Mecham et al. 2010) and increase the risk of 
metabolic syndrome and diabetes mellitus (Holmqvist et al. 2014). It seems likely 
that such conditions could appear or worsen during pregnancy and, thus, 
complicate pregnancies of survivors. Many pregnancy-related conditions, as well as 
preterm deliveries are associated with an increased risk for medical interventions 
during pregnancy and labor (Martin et al. 2007), so we also wanted to assess 
adverse delivery outcomes in cancer survivors. Some studies have reported an 
increased risk for Cesarean sections, but when it comes to induction of labor and 
other obstetric outcomes, there are few and partly conflicting reports (Clark et al. 
2007, Mueller et al. 2009, Haggar et al. 2014, Reulen et al. 2017). 
 
The studies of this thesis focus not only on fertility treatments but also on 
pregnancy-related conditions and adverse obstetric outcomes in female cancer 
survivors. This information can help clinicians to identify cancer survivors requiring 
fertility counselling or fertility preservation and those at risk for adverse obstetric 
outcomes. It could also contribute to the development of guidelines for the follow 
up of pregnancies and management of deliveries in cancer survivors. 
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 REVIEW OF THE LITERATURE 
2.1 EARLY ONSET CANCER INCIDENCE AND SURVIVAL 
2.1.1 CHILDHOOD CANCER 
 
Childhood cancer is defined as cancer diagnosed at the ages of 0-14 years (National 
Cancer Institute 2018). The incidence rate of childhood cancer has remained stable 
in Finland (annual standardized incidence rate in 1988-1997 was 173.2 per million) 
and is higher than Europe´s overall (annual standardized incidence rate of 139.5 per 
million) (Spix et al. 2006, Madanat et al. 2014). The higher incidence rate in Finland 
is consistent with rates in the other Nordic countries (Kaatsch et al. 2010) and is 
believed to be due to the high completeness of registration, though true variations 
in underlying risk cannot be ruled out (Leinonen et al. 2017). 
 
The current survival rates in Scandinavia are among the highest in the world 
(80.9% during 1991-2000 in Finland) (Madanat et al. 2014, Gatta et al. 2014). 
According to the Finnish Cancer Registry data, the most common childhood cancer 
diagnoses in Finland during 2015 were, in descending order (Figure 1A): leukemia 
(31.2%), tumors of the central nervous system (CNS) (23.4%) and lymphomas (10.7%) 
(Engholm et al 2018). Regarding leukemia, the five-year survival rate in Finland in 
1991-2002 was higher than in rest of Europe during 1993-1997 (81.5% compared to 
77%) (Madanat et al. 2014). The high leukemia survival rates in Finland are the result 
of a long history of collaboration between the Nordic countries with the aim of 
standardizing and improving the treatment of childhood leukemia (Coebergh et al. 
2006, Madanat et al. 2014). The third most common cancer type among children, 
lymphomas, are divided into Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma 
(NHL). The five-year survival rates for Finnish HL children is 97.2% in the most recent 
diagnostic period of 2001-2010, whereas the rates are a little lower at 88.7% for NHL 
children. The survival rate for tumors of the CNS is the lowest of these three most 
common pediatric malignancies, at 75.4% in the most recent era studied (Madanat 
et al. 2014).  
2.1.2 CANCER IN FEMALE ADOLESCENTS AND YOUNG ADULTS 
  
The definition of cancer in adolescence and young adults (AYA) has varied 
regionally with both 15-19 and 15-39 years age ranges. However, the age range now 
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accepted by the European Network for Cancer in Children and Adolescents is a cancer 
diagnosis between 15 and 39 years of age (Desandes 2016). The cancer spectrum 
shifts towards carcinomas and epithelial neoplasms with increasing age, and typical 
childhood cancers (such as leukemia and tumors of the CNS) becomes rarer (Ferreira 
et al. 2013). The studies included in this thesis have, therefore, further subdivided 
AYAs into those being diagnosed at the ages of 15 to 24 years (adolescents) and those 
diagnosed at the ages of 25 to 34 or 39 years (young adults).  
 
According to Finnish Cancer Registry data, the most common cancers among 
female AYAs in Finland during 2015 were, in descending order (Figure 1B): breast 
cancer (22.9%), cancer of the thyroid (15.2%) and melanoma (15.1%) (Engholm et al. 
2018). Attention has been drawn to the fact that adolescents (aged 15-24 years) 
show poorer survival rates than childhood cancer patients (Gatta et al. 2009). One 
reason is believed to be delays in diagnosis and cancer treatment (Ofran et al 2014, 
Ferrari et al 2012). As a result, different initiatives have been undertaken in several 
European countries with the goal of improving cancer screening methods and 
collaboration between pediatrics and adult oncologists in specific treatment units 
(Stark et al 2015). This has led to increasing cancer survival rates among AYAs in 
Europe, being 79% in 1999-2002 and 82% in 2005-2007 (Trama et al. 2016). The 
survival rate for Finnish AYAs aged 15-19 years was 83% in 2000-2007 and 91.7% for 
those aged 20-39 years (Trama et al. 2016). However, in certain leukemias, 
lymphomas and sarcomas, the survival rates still remain significantly worse in AYAs 
compared to cancer patients diagnosed in childhood (Trama et al. 2016). 
 
Concerning survival rates (European figures) for the most common cancer types 
in Finnish female AYAs, patients with breast cancer had a survival rate of 83.5%, 
cancer of the thyroid a survival rate of 99.2%, and melanomas a survival rate of 88.9% 
















Figure 1. Incidence rates for the 7 most common cancers at the age of 0-14 years (A) and at 
the age of 15-39 years (B). Published with the permission of NORDCAN (Engholm et al. 2018) 
A 
B 
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2.2 THERAPIES FOR EARLY ONSET CANCER 
Cancer therapies are generally divided into three main modalities: surgical 
treatment, radiotherapy and chemotherapy. Hematological malignancies are 
typically managed with combination chemotherapy (Mehta et al. 2011) and solid 
tumors with surgery, radiotherapy and chemotherapy (Grosfeld et al. 1999). In some 
cancer types (the most common one being leukemia), myeloablative high-dose 
chemotherapy, followed by a hematopoietic stem cell transplant (HSCT) may be used 
in high-risk cases (Passweg et al. 2014). Newer types of treatment include 
immunotherapy and specific, targeted therapy drugs (Vanneman et al. 2012).  
2.2.1 CHILDHOOD CANCER                   
 
The notable increase in survival rates after childhood cancer is due to the 
introduction of chemotherapy in the 1960s (Jones et al. 1987), allowing multi-
modality treatment with surgery and radiotherapy. The five-year survival increased 
as a result from 20-30% in the 1960s (Birch et al. 1988) to over 80% today (Madanat 
et al. 2014).  
 
When new combinations of cancer treatments, including chemotherapy, became 
available, the dose and volume of radiotherapy could be gradually decreased or, in 
some cases, even excluded (Hudson et al. 2012). In one study, 77% of all cancer 
patients under 21 years of age received radiotherapy during 1970-1979 compared to 
33% in 1990-1999 (Turcotte et al. 2017). Another study divided childhood cancer 
survivors into those receiving cranial irradiation, chest irradiation and abdominal 
irradiation (Armstrong et al. 2016). This study found that, between the 1970s and 
1990s, cranial irradiation among patients with acute lymphoblastic leukemia had 
decreased from 85% to 19%, chest irradiation among HL patients decreased from 
87% to 61% and for abdominal irradiation among Wilms´tumor patients decreased 
from 78% to 43% (Armstrong et al. 2016). At the same time, progress in radiation 
technology led to better protection of healthy tissue in cancer patients who still 
needed radiotherapy (Hudson et al. 2012). This is crucially important, since 
therapeutic irradiation has been strongly connected with secondary malignancies, 
pulmonary and cardiac dysfunction and damage to the ovaries (Armstrong et al. 
2010, Green et al. 2010). According to a recent study, children diagnosed with cancer 
in the 1990s had a lower risk for secondary malignancies at 15 years after initial 
cancer diagnosis compared to those treated in the 1970 (Turcotte et al. 2017). In that 
study, the lower risk for secondary malignancy was associated with a reduction in the 
therapeutic radiation dose. Further, Armstrong et al.´s study (2010) observed a 
reduction in 15-year mortality (from 12.4% to 6.0% between 1970s and 1990s). The 
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reduction was attributed to the decrease in death from secondary malignancy, 
cardiac and pulmonary causes (Armstrong et al. 2016). 
 
Chemotherapeutic agents, especially anthracyclins, alkylating agents (divided 
into classical alkylating agents and platinum-based, alkylating-like agents) and 
epipodophyllotoxins, have also been associated with an increased risk of secondary 
malignancies (Kim et al. 2015, Pole et al. 2015). As the use of radiotherapy has 
decreased, the proportion of survivors receiving anthracyclins, alkylating agents and 
epipodophyllotoxins is increasing (Turcotte et al. 2017). An increase in the median 
cumulative dose for epipodophyllotoxins and platinum based alkylating-like agents 
was observed from 1970-1999, whereas the median cumulative dose for classical 
alkylating agents and anthracyclins had decreased (Turcotte et al. 2017).  
 
Anthracyclins, which are used in 50-60% of childhood cancer cases (Smith et al. 
2010) are known for their cardiotoxic late effects and increased risk for secondary 
leukemia (Le Deley et al. 2003). Furthermore, alkylating agents are known to cause 
dose-related gonadal damage. Of these alkylating agents, cyclophosphamide and 
busulfan, commonly used in childhood cancers (Afify et al. 2000), are considered 
particularly harmful for the ovaries (Morgan et al. 2012). Epipodophyllotoxins have 
been associated with an increased risk for secondary acute myelogenous leukemia 
(Le Deley et al. 2003). 
2.2.2 CANCER IN ADOLESCENTS AND YOUNG ADULTS 
 
AYA patients have been referred to as “the lost tribe” since less attention has 
been given to this cancer group compared to childhood cancer patients and adult 
cancer patients (Fernandez et al. 2006). Malignant epithelial neoplasms become 
more common (breast cancer, thyroid cancer and melanoma) in AYAs and surgical 
treatment usually plays a bigger role than in childhood cancer patients (Bleyer et al. 
2009). The cancers in AYAs have been shown to have a different biology and 
pathogenesis than cancers in children and adults, probably explaining the poorer 
survival rates for some cancers among AYAs (Trama et al. 2016).  Diagnosis and 
treatment tailored to the specific histopathologic cancer types might improve the 
survival rates (Bleyer et al. 2008).  
 
AYAs with breast cancer (the most common cancer type in female AYAs) generally 
have poorer survival rates than older adults, as the breast cancer typically has a more 
aggressive phenotype (Keegan et al. 2012). Although general principles for using 
chemotherapy and targeted agents are the same for breast cancer in AYAs and older 
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adults, use of endocrine therapy varies in pre- and postmenopausal women (Tichy et 
al. 2013). Approximately 60% of breast cancers diagnosed under the age of 50 years 
are estrogen receptor positive diseases (Anderson et al. 2002). The standard care for 
estrogen receptor positive breast cancers is adjuvant endocrine therapy with 
tamoxifen for at least five years. Suppression of ovarian estrogen production (by 
administering luteinizing hormone-releasing hormone agonists), oophorectomy or 
ovarian ablation in premenopausal women have yielded conflicting results and more 
studies are needed (Theriault et al. 2013, Smyth et al. 2015).  
 
The overall survival rate for thyroid cancer (99.2%) is one of the highest among 
all types of cancers in AYAs (Trama et al. 2016). Based on an American study (Hay et 
al 2017), most AYAs with thyroid cancer are treated similarly to adult thyroid cancer 
patients, even though recent guidelines suggest a more conservative approach with 
less complications (Francis et al. 2015). Two different approaches are available for 
AYAs: radical treatment or a more conservative approach (Massimino et al. 2018). 
The radical treatment includes total thyroidectomy and lymphadenectomy (in cases 
of lymph-node metastases), followed by radioactive iodine treatment. Common 
postoperative complications after radical surgery include hypoparathyroidism 
(Massimino et al. 2006) and recurrent laryngeal nerve palsy (Sosa et al. 2008). Late 
effects after radioactive iodine treatment include infertility, salivary gland 
dysfunction and an increased risk for secondary malignancy (Lee et al. 2010). This 
therapy should only be used in high-risk patients, taking the possible late effects into 
account (Francis et al. 2015, Massimino et al. 2018). A more conservative approach, 
removing only the affected thyroid lobe and only the lymph node with metastases, 
is often recommended for AYAs (Collini et al. 2006). A recent study concluded that 
individual treatment that takes the clinical presentation and histopathologic type of 
the thyroid cancer into account is recommended (Spinelli et al. 2016). 
 
Melanoma is the third most common cancer, accounting for 15.1% of all cancers 
in female AYAs in Finland (Engholm et al. 2018). The incidence of melanoma is 
increasing, especially in female AYAs (Davar et al. 2016). It is estimated that 75% of 
all melanomas diagnosed in subjects under 30 years of age are due to exposure to 
natural or artificial sunlight (Sender et al. 2015). Education on sun safety and skin 
self-examination are vital, especially since it is difficult to change the health 
behaviors of AYAs (Sender et al. 2015). As melanomas in AYAs are genetically similar 
to those of adults, the treatment is also the same, although more attention is needed 
on psychosocial support and encouragement to participate in clinical trials (Davar et 
al. 2016). 
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The survival rates are worse in AYAs compared to childhood patients for certain 
leukemias, lymphomas and sarcomas, (Trama et al. 2016). Special treating units with 
a multidisciplinary team have been suggested to improve survival rates for AYAs that 
will, hopefully, increase the cooperation between pediatric and adult oncologists and 
increase the likelihood of participation in clinical trials (Stark et al. 2015). 
2.3 LATE EFFECTS OF CANCER AND ITS TREATMENT 
Late effects of cancer are defined as health problems that occur months or years 
after the cancer treatment has ended (National Cancer Institute 2018). Often used 
synonyms are adverse events and late sequelae. Adverse events are defined as 
unfavorable and unintended events with abnormal clinical findings that are 
associated with the use of cancer treatment (National Cancer Institute 2018). This 
term is used for both acute and chronic complications, often in the context of 
management of chemotherapy administration and dosing and in clinical trials 
(National Cancer Institute 2018). Late sequelae of cancer is defined as a chronic, 
pathological condition often resulting from the primary disease/injury (Oxford 
Dictionary 2018). In this thesis, the term “late effects of cancer” includes both 
adverse events and late sequelae of cancer. 
 
According to different studies (Armstrong et al. 2014, Hudson et al. 2013, Bhakta 
et al. 2017), 60% to 90% of all cancer survivors will have at least one or more chronic, 
health-related conditions later in life. By the age of 50 years, 50% of the childhood 
cancer survivors have experienced a late effect that is categorized as severe, 
disabling, or life-threatening morbidity or death compared to 20% of their siblings 
(Armstrong et al. 2014). Factors related to the cancer type and cancer treatment can, 
to some extent, predict the risk for late effects in cancer survivors (National Cancer 
Institute 2018). However, for an individual cancer patient, host-related factors 
should also be taken into account when assessing the risk for late effects (National 
Cancer Institute 2018). Figure 2 describes these factors in more detail. 
2.3.1 SECONDARY MALIGNANCIES 
 
Subsequent malignant neoplasms (SMNs) are defined as histologically distinct 
neoplasms occurring at least two months after the treatment of the primary cancer 
has ended (National Cancer Institute 2018). SMNs are the most common reasons for 
non-relapse, late mortality in cancer survivors. A recent study showed that 58% of all 
deaths occurring five years or more after initial cancer diagnosis, are due to SMNs  
(Mertens et al. 2008). A Nordic study on cancer survivors diagnosed under 19 years 
































   
of age (Olsen et al. 2009) found a 3.3-fold increased risk of SMNs compared to the 
general population. Sex and age at cancer diagnosis are risk factors for SMNs. 
According to one study, women had a higher risk for SMN compared to men, 
probably explained by secondary breast cancer (Friedman et al. 2010). The most 
common SMNs in females were breast cancer, thyroid cancer, non-melanoma skin 
cancer and meningioma (Friedman et al. 2010). Age at primary cancer diagnosis has 
been found to be an important risk factor, as children under 10 years of age have an 
increased risk for meningioma, malignant CNS tumors, sarcomas, and thyroid cancers 
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Figure 2 Factors that should be considered when assessing the risks for late effects of 
cancer and its treatments (National Cancer Institute 2018) 
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(Neglia et al. 2001). Breast cancer, non-melanoma skin cancer, and other solid organ 
cancers (including head and neck, small intestine, and colorectal cancers) were the 
most common ones in survivors aged 15-21 years at cancer diagnosis (Friedman et 
al. 2010). Treatment-related risk factors for secondary malignancies included 
exposure to radiotherapy, as well as treatment with high doses of anthracyclins, 
alkylating agents and epipodophyllotoxins (Mertens et al. 2008, Pole et al. 2015). 
SMNs due to chemotherapy are characterized by a short latency, meaning that the 
increased risk for SMN is observed during a limited time period, with a peak time of 
between three to nine years from treatment (Blayney et al. 1987). Instead, there is 
generally a long latency of two to three decades for SMNs due to radiotherapy 
(Metayer et al 2000). 
2.3.2 CARDIOVASCULAR LATE EFFECTS 
 
Cardiovascular disease, is the third most common cause of late mortality in 
childhood and AYA cancer survivors, after SMNs and pulmonary morbidity (Kremer 
et al. 2001, Mertens et al 2008). According to a Finnish study (Kero et al. 2014), cancer 
survivors diagnosed below 35 years of age had an increased risk for cardiomyopathy, 
atherosclerosis, cardiac ischemia and cardiac arrhythmia. Treatment-related factors 
associated with an increased risk for cardiovascular late effects are certain 
chemotherapies, including anthracyclins, alkylating agents, antimetabolites and anti-
microtubule agents (Simbre et al. 2005) as well as radiotherapy (Swerdlow et al. 
2007). According to two studies (Aleman et al 2007, van der Pal et al 2012), the 
combination of mediastinal radiotherapy and anthracyclins was associated with the 
highest risk for cardiovascular late effects. Among survivors exposed to cardiac-
directed radiotherapy, 56.4% experienced cardiac late effects in the form of mild to 
moderate heart valve abnormalities (Hudson et al. 2013). 
 
Cardiotoxicity can be divided into early toxicity, usually appearing within hours to 
weeks but less than a year from cancer treatment, and late toxicity, which occurs 
more than a year from cancer treatment, usually 10-20 years later (Koutsoukis et al. 
2018). Risk factors for cardiovascular late effects included early toxicity, higher dose 
of anthracyclins and mediastinal radiotherapy, young age at cancer diagnosis, 
increasing time since cancer treatment and female sex (Armstrong et al. 2007). 
According to one study (Krischer et al 1997), female cancer survivors treated with 
anthracyclins have an almost two-fold increased risk for sudden death, congestive 
heart failure or cardiotoxicity compared to male cancer survivors. In Green et al.´s 
study (2001), female Wilms` tumor survivors have a 4.5-fold increased risk of being 
treated with digoxin or diuretics for congestive heart failure compared to male 
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cancer survivors. It is recommended that cancer survivors with an increased risk for 
cardiomyopathy and congestive heart failure undergo surveillance starting two years 
after the completion of cardiotoxic therapy and continuing every five years 
thereafter (Armenian et al. 2015). 
2.3.3 METABOLIC SYNDROME AND GASTROINTESTINAL LATE EFFECTS 
 
The National Cholesterol Education Program has defined metabolic syndrome as 
the presence of three or more of the following components: increased waist 
circumference, elevated triglycerides, reduced HDL-Cholesterol, elevated blood 
pressure and elevated fasting glucose (Alexander et al. 2003). Metabolic syndrome 
is associated with an increased risk for type 2 diabetes mellitus (DM) and 
atherosclerotic disease (Eckel et al. 2005). 
 
Early onset cancer survivors treated with cranial radiotherapy and total body 
irradiation in combination with chemotherapy have an increased risk for metabolic 
syndrome (Taskinen et al. 2007, van Waas et al. 2010, Nottage et al. 2014). A study 
on survivors with hematologic malignancies (Trimis et al. 2007) showed that cranial 
radiotherapy is associated with the highest risk for metabolic syndrome. In that 
study, 22% of survivors treated with a combination of cranial radiotherapy and 
chemotherapy were found to have metabolic syndrome, whereas only 8% of those 
being treated with chemotherapy alone suffered from it (Trimis et al. 2007). Another 
study comprising 500 childhood cancer survivors found that total cholesterol levels 
and systolic blood pressure were higher in female cancer survivors compared to 
healthy female controls (van Waas et al. 2010). This study also found an increased 
risk for obesity among cancer survivors treated with cranial radiotherapy (van Waas 
et al. 2010). A study of childhood acute lymphoblastic leukemia survivors, who were 
treated with cranial radiotherapy found a more than 2.5-fold increased risk for 
obesity compared to siblings (Oeffinger et al. 2003). A threefold higher risk of 
infertility has been shown in obese women compared to non-obese women (Wise et 
al. 2010). Furthermore, overweight is associated with negative outcomes for women 
undergoing IVF, due to poor oocyte quality and lower preimplantation (Bellver et al. 
2010). 
 
Two studies on DM (type 1 and 2 combined) found a 1.6-1.8-fold increased risk in 
cancer survivors compared to siblings or the general population (Mecham et al. 2009, 
Holmqvist et al. 2014). The increased risk is associated with total body irradiation, 
abdominal irradiation and alkylating agents, as well as younger age (0-4 years) at 
diagnosis (Mecham et al. 2009). Leukemia, neuroblastoma, germ-cell and CNS 
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neoplasms, Hodgkin`s lymphoma, as well as malignant bone and Wilms´ tumor, are 
associated with an increased risk for DM (Mecham et al 2009, Holmqvist et al. 2014, 
Gunn et al. 2015). 
 
Concerning gastrointestinal late effects and liver diseases, a Scandinavian study 
found a 60% higher risk for these outcomes in cancer survivors compared to the 
general population (Asdahl et al. 2016). Survivors of hepatic tumors, neuroblastomas 
and leukemia have the highest excess risk for gastrointestinal late effects and liver 
diseases (Asdahl et al. 2016). Specific late effects that are increased among cancer 
survivors include constipation, which has a big impact on quality of life, and liver 
cirrhosis, which increases the mortality. Another study (Goldsby et al. 2011) found 
similar results but in addition, the risk for colostomy/ileostomy and liver biopsy was 
increased.  
2.3.4 LATE EFFECTS OF THE ENDOCRINE SYSTEM 
 
According to a recent study, 48% of all childhood cancer survivors will suffer from 
endocrine late effects, and the risk generally increases with time from the cancer 
diagnosis (Brignardello et al. 2013). Endocrine late effects in females can be divided 
into those resulting from damage to the hypothalamic and/or pituitary gland 
(including deficiency of growth hormone, gonadotropins, thyrotropins and 
corticotropins) and damage affecting the peripheral organs (ovaries, thyroid and 
adrenal glands) (Constine et al. 1993). Damages to the ovaries (primary 
hypogonadism) will be covered in a separate section. 
 
Cranial radiotherapy affects the hypothalamic, pituitary and thyroid gland 
negatively (Nandagopal et al. 2008, Chemaitilly et al. 2015). According to a recent 
study on childhood cancer survivors treated with cranial radiotherapy (Chemaitilly et 
al. 2015), 46.5% suffered from growth hormone deficiency, 10.8% from central 
hypogonadism and 7.5% from thyrotropin deficiency. Similar results are found in a 
Scandinavian study (de Fine Licht et al. 2014), in which childhood cancer survivors 
have a 4.8-fold increased risk of a hospital contact for endocrine disorders. In that 
study, pituitary hypofunction is the most common disorder, followed by 
hypothyroidism and dysfunction of the gonads. The risk is highest among leukemia 
survivors and those treated for CNS tumors (de Fine Licht et al. 2014). HSCT also 
increases the risks for several endocrine disorders in cancer survivors (including poor 
growth, hypogonadism, hypothyroidism and osteopenia), especially since it is often 
carried out in combination with total body irradiation (Nandagopal et al. 2008). 
Overall, the risk for endocrine late effects after chemotherapy are considered less 
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common compared to those after radiotherapy, with the exception of ovarian 
dysfunction (Nandagopal et al. 2008). 
 
Cranial radiotherapy, which can lead to central hypogonadism, can appear as 
arrested puberty, pubertal delay or symptoms of decreased sex hormone production 
depending on age and pubertal status at time of treatment (Meistricht et al. 1997, 
Chemaitilly et al. 2015). In small radiation doses, gonadotropin deficiency can occur 
after several years. However, with cranial radiotherapy at a dose of more than 35G, 
up to 20% will experience symptoms of gonadotropin deficiency within 10 years post-
treatment (Armstrong et al. 2009). Childhood cancer survivors have an increased risk 
for hypothyroidism, which is dependent on the cancer type (Madanat et al. 2008, 
Brignardello et al. 2013). Childhood cancer survivors of thyroid cancer, CNS tumor 
and HD, have the highest risk for hypothyroidism, probably because the radiation 
field included the thyroid (Madanat et al. 2008). 
2.3.5 NEUROCOGNITIVE LATE EFFECTS 
 
Neurocognitive and psychological late effects can occur as intellectual decline, 
memory loss, attention deficit and behavioral problems (Kadan-Lottick et al. 2010). 
It is often difficult, however, to separate neurocognitive late effects due to cancer 
treatment from other psychosocial factors related to every day life as a cancer 
patient, such as the hospital environment, missing out on school and lack of social 
stimulation (Brown et al. 1993). According to one study (Nandagopal et al. 2008) 
almost 50% of all childhood cancer survivors had neurocognitive problems. Cancer 
survivors who were treated with cranial radiotherapy have been reported to have 
the highest risk for neurocognitive late effects, although the risk is also increased 
after intrathecal chemotherapy and systematic therapy, especially with high-dose 
methotrexate or cytarabine (Nathan et al. 2007, Wefel et al. 2008). Patients with 
acute lymphoblastic leukemia and brain tumors have the highest risk for 
neurocognitive late effects (Nathan et al. 2007). Other risk factors are female sex and 
younger age at cancer diagnosis (Khan et al. 2015, Ellenberg et al. 2009). According 
to a Finnish study, female cancer survivors receiving cranial irradiation and 
chemotherapy below the age of seven years have poorer school performance 
compared to controls (Harila-Saari et al. 2007). 
2.3.6 PSYCHOSOCIAL LATE EFFECTS 
 
The majority of early onset cancer survivors report a reduced quality of life, which 
is believed to be partially due to different late effects (Yeh et al. 2016). Reports on 
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psychological distress and other mental health problems are partly conflicting. In 
three studies, survivors who have undergone cranial radiotherapy (van der Geest et 
al. 2013), brain surgery (Vuotto et al. 2017), as well as those treated with 
anthracyclins (Sun et al. 2011), have an increased risk for mental health problems. In 
general, cancer survivors reporting pain and worsening health status also had an 
increased risk for anxiety and depression (Brinkman et al. 2013). Another study found 
mental health problems in cancer survivors treated with anthracyclins to be 
connected to cardiovascular late effects (Spewak et al 2017). Regarding host-related 
factors, an increased risk for psychological stress is related to female gender, lower 
education, unemployment and unmarried status (Zeltzer et al. 2008). 
 
Two studies report higher rates of psychological distress and psychosocial 
problems among cancer survivors diagnosed as adolescents compared to childhood 
cancer survivors (Mody et al. 2008, Krull et al. 2010). According to a third study, 
adolescents are particularly challenged socially, and the cancer diagnosis and 
treatment sometimes interferes with detachment from parents (Johannsdottir et al. 
2010). Krull et al.´s study (2010) found that adolescents, aged 12-17 years, have an 
increased risk for attention deficit disorders and emotional problems compared to 
siblings (Krull et al. 2010).  
 
Most studies found no increased risk for depression in cancer survivors (Parslow 
et al. 2000, Kazak et al. 2010, Yeh et al. 2016). In many studies, however, outcomes 
are evaluated based on hospital data, thus missing the less severe (but probably 
more common) cases treated in primary care (Parslow et al. 2000). Cancer survivors 
in an American study reported medication use for anxiety and depression at rates 
nearly two times those reported by the general population (Hawkins et al. 2017). A 
Norwegian study found a 19% higher use of antidepressants in cancer survivors 
diagnosed below the age of 25 years compared to age-matched controls. The risk 
was highest for survivors of CNS tumors and leukemia (Johansdottir et al. 2017). 
2.3.7 LATE EFFECTS ON THE FEMALE REPRODUCTIVE SYSTEM 
2.3.7.1 The ovaries 
 
In addition to gonadotropin secretion-related damage (central hypogonadism), 
cancer survivors are also at risk of gonadal dysfunction related to the ovaries (primary 
hypogonadism) (Sklar et al. 1999). Abdominal radiotherapy, as well as HSCT and 
chemotherapy with alkylating agents, can damage the ovaries (Wallace et al. 1989, 
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Chemaitilly et al. 2006, Vatanen et al. 2014). The ovaries of prepubertal girls are 
generally considered more resistant to damage from chemotherapy and 
radiotherapy compared to adult women´s ovaries (Meistricht et al. 1997). When 
ovarian failure occurs before puberty onset, it will result in delayed puberty and 
primary amenorrhea. If ovarian failure occurs after puberty, it will cause secondary 
amenorrhea and/or menopausal symptoms (Meistricht et al. 1997, Webber et al. 
2016). Ovarian insufficiency is often the reason for infertility in cancer survivors 
(Webber et al. 2016, Levine et al. 2018). 
The loss of ovarian function within five years after cancer treatment is referred 
to as acute ovarian failure (Chemaitilly et al. 2006). If the ovaries cease to function 
many years after cancer treatment but before the age of 40 years, the term 
premature menopause or premature ovarian insufficiency (POI) is used (Byrne et al. 
1999, Webber et al. 2016). Thus, the presence of apparently normal ovarian function 
at the completion of cancer treatment does not rule out ovarian damage. According 
to a study (Chemaitilly et al. 2006) on childhood cancer survivors, 6.3% developed 
acute ovarian failure after cancer treatment. The risk seemed to increase with 
advancing age at cancer diagnosis and more than half of the survivors with acute 
ovarian failure had received ovarian irradiation of at least 10 Gy (Chemaitilly et al. 
2006). A recent study on premature menopause (Levine et al. 2018) found that the 
prevalence of non-surgical premature menopause in cancer survivors at the age of 
40 years was 9.1% and the risk compared to siblings was more than ten-fold. 
2.3.7.2 The uterus 
 
Cancer treatments, especially abdominal radiotherapy, have been shown to 
damage the uterus (Beneventi et al. 2015). In one study, childhood cancer survivors 
who received abdominal radiotherapy had an up to 40 % smaller uterine volume, 
compared to those who received chemotherapy (Larsen et al. 2004). Another study 
found reduced uterine blood flow and uterine fibrosis among adult cancer survivors 
treated with radiotherapy before puberty (Critchley et al. 1999). Researchers 
believed for many years that chemotherapy had little or no impact on uterine 
function (Nicholson et al. 1993). A recent study, however, shows that busulfan in 
combination with bone marrow transplantation increases the risk of uterine damage 
(Beneventi et al. 2015). The data are limited on the effect of chemotherapy alone on 
the uterus. Uterine damage due to cancer treatment often develops slowly, so the 
risk for late effects increases with a woman´s advancing age (Beneventi et al. 2015). 
The risk of uterine damage as a consequence of abdominal radiotherapy and 
chemotherapy has also been found to increase in a dose dependent manner (Green 
et al. 2010). 
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2.4 PARENTHOOD IN CANCER SURVIVORS 
Europe is the continent with the most rapid fall in fertility rates (Lutz et al. 2006). 
The fertility rate in Finland decreased for the eighth year in a row in 2018, at 1.40 
births per woman (Statistics Finland 2018) (Figure 3). Explanations for the declining 
fertility rates in Europe are complex and differs among countries (Gauthier et al. 
2007). Generally, the number of couples not having children and those having fewer 
children have increased during recent years, as well as the number of couples 







The probability of early onset cancer survivors marrying and/or having children 
post-diagnosis is reduced by up to 50% compared to their siblings and the general 
population (Madanat et al. 2008, Pivetta et al. 2011). The reduced probability for 
parenthood is most likely not only due to reduced pregnancy rates; cancer survivors 
and their spouses are less motivated to have children because of the experienced 
cancer (Oosterhuis et al. 2008). Studies based on questionnaire data have found that 
the desire to have children is lower in childhood cancer survivors than in the general 
population (Reinmuth et al. 2008). Cancer survivors are concerned about the health 
of future offspring and the recurrence of their own cancer. They are also worried 
about educational and financial setbacks as an effect of the cancer treatment and 
have expressed difficulties in finding a partner and conceiving (Reinmuth et al. 2008). 
According to one study, female cancer survivors living in a relationship have a 1.8-
fold increased risk for divorce/separation compared to healthy controls (Kirschhoff 
Figure 3 Total fertility rate in Finland during 1900 to 2018. Modified from Statistics 
Finland (2019) 
1900 1910 1920 1930 1940 1950 1960 1970 1980 1990 2000 2010 2018
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et al. 2012). Generally, however, experiencing cancer increases the value placed on 
family and the importance of parenthood (Langeveld et al. 2002, Schover et al. 2002). 
According to one survey (Mancini et al. 2011), no association existed between 
motivation to have children and cancer type, age of the patient or time elapsed from 
cancer diagnosis. 
 
As more women decide to delay childbirth, the risk increases for receiving a 
cancer diagnosis before the family is complete (Nabukera et al. 2006, Canada et al. 
2012). A rapid increase in the survival rates of early onset cancer patients has led to 
changing attitudes towards parenthood and childbearing among cancer survivors 
and health-care providers (Peccatori et al. 2013). Historically, especially female 
breast cancer survivors were discouraged from having children (Holleb et al. 1965). 
It was believed that high levels of ovarian estrogens and progestins, pituitary 
prolactin and placental hormones during pregnancy could affect possible 
microscopic tumor tissue in the body and lead to a recurrence of cancer (Holleb et 
al. 1965). Nowadays, pregnancies after cancer are considered safe, and cancer 
survivors should not be discouraged from having children after their cancer 
treatment (Peccatori et al. 2013). A meta-analysis of 14 retrospective control-studies 
even found a 41% lower risk of death among female breast cancer survivors who 
conceived when compared to those who did not (Azim et al. 2011). 
 
There are no standard recommendations concerning the ideal time interval 
between cancer treatment and pregnancy (Lambertini et al. 2016). Two aspects 
should be considered: firstly, the biological effects of the anticancer treatment on 
the body of the mother should be sufficiently small to not harm the development of 
the fetus; secondly, the interval should be long enough to minimize the risk for cancer 
relapse (Lambertini et al. 2016). Individual timing based on the risk of relapse, age of 
the woman and ovarian reserve is recommended (Peccatori et al. 2013). A time 
interval of two years following cancer diagnosis is generally recommended for breast 
cancer patients (Peccatori et al. 2013). Adjuvant tamoxifen treatment for at least five 
years after diagnosis is recommended in estrogen receptor positive breast cancer 
patients. Insufficient data exists to date to support the safe interruption of tamoxifen 
and attempting pregnancy before the five-year treatment period is completed 
(Lambertini et al. 2016). One study that compared estrogen receptor positive breast 
cancer survivors who became pregnant to those who did not, found no difference in 
the disease-free interval (Azim et al. 2013). Furthermore, when comparing estrogen 
receptor positive survivors who became pregnant within two years of cancer 
diagnosis to those who became pregnant later, no difference was found in the 
disease-free interval (Azim et al. 2013). However, the study lacked statistical power 
to address the safety of early tamoxifen interruption (Azim et al. 2013). 
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2.5 FERTILITY IN CANCER SURVIVORS 
2.5.1 SUBFERTILITY AND INFERTILITY 
 
The International Committee for Monitoring Assisted Reproductive Technologies 
(ICMART) defines infertility as “a disease characterized by the failure to establish a 
clinical pregnancy after 12 months of regular, unprotected sexual intercourse or due 
to an impairment of a person´s capacity to reproduce either as an individual or with 
his/her partner” (Zegers-Hochschild et al. 2017). Couples with a high probability of 
conception will often conceive within one to four cycles, whereas a couple with low 
probability of conception may need many cycles of trying (Wilcox et al. 1988). These 
couples are often referred to as subfertile (reduced in their chances of conceiving 
compared to other couples). Couples with no chance of conceiving are sterile. Many 
subfertile couples seeking help for infertility could probably conceive without 
medical treatment if they would only try longer (Taylor et al. 2003).   
 
The prevalence of infertility is increasing worldwide and is now estimated to be 
13-16% among the Western population (Terävä et al. 2008, Datta et al. 2016). Self 
reported lifetime subfertility in Finland is 16% (Terävä et al. 2008). The reasons for 
the increasing prevalence of infertility are numerous and vary in different parts of 
the world (Datta et al. 2016). Lifestyle and nutritional factors, infections due to 
sexually transmitted diseases and post-abortion complications are believed to play a 
central role (Mascarenhas et al. 2012 and Petraglia et al. 2013). Delaying childbearing 
until later in life, exposure to chronic stress and environmental pollutants as well as 
gonadotoxic cancer treatments damaging the reproductive system, play a larger role 
in western countries (Petraglia et al. 2013).  
 
According to ICMART, the most common causes of female infertility can be 
divided into ovulatory disorders (including ovulatory disturbances and diminished 
ovarian reserve), tubal factors, endometriosis, uterine/cervical factors and 
unexplained infertility (Figure 4) (Zegers-Hochschild et al. 2017). According to a 
systematic review from the United Kingdom (Bhattacharya et al. 2010), 10-20% of all 
infertility cases are unexplained. Ovulatory disorders accounted for 27%, tubal 





















Figure 4 Different causes for female infertility (Zegers-Hochschild et al. 2017) 
 
 
Many studies have shown that cancer survivors have decreased rates for 
parenthood, pregnancy and live birth compared to siblings or the general population 
(Table 1). The potential fertility issues are a big concern among cancer survivors and 
parents of childhood cancer survivors (Taylor et al. 2016). However, pregnancy rates 
vary based on cancer type, according to a Norwegian study (Stensheim et al. 2011). 
As an example, treatment of melanoma or thyroid cancer do not decrease pregnancy 
rates compared to controls, whereas survivors of leukemia, cervical and breast 
cancer have the lowest pregnancy rates (Stensheim et al. 2011). In one study (Green 
et al. 2009) hypothalamic/pituitary irradiation of more than 30 Gy, as well as 
radiation doses of more than 5 Gy on the ovaries, decreases the possibility of ever 
becoming pregnant in cancer survivors. Use of alkylating agents was also associated 
with lower pregnancy rates in cancer survivors (Green et al. 2009). 
 
Parenthood and pregnancy rates are indirect measurements of the potential 
harm caused by cancer and its treatments on the reproductive system, as other 
factors will also affect the likelihood of becoming pregnant and a parent (the wish to 
have children and finding a partner, to name a few) (van Dorp et al. 2018). Gonadal 
function is a more direct measurement when estimating subfertility or infertility 
caused by cancer treatments; although similar to pregnancy rates, it does not take 
into account the actual wish for a pregnancy or whether there was an attempt to 
become pregnant. Gonadal injury can manifest as POI and infertility (Anderson et al. 
2015). In one study (Sklar et al. 2006), comprising 2819 cancer survivors and 1065 
female siblings, the cumulative incidence for non-surgical POI was 8% among cancer 
survivors and 0.8% among their siblings. The incidence was almost 30% for cancer 
survivors treated with both alkylating agents and abdominal radiotherapy. In 
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associated with a higher risk for POI (Sklar et al 2006).  According to a recent study 
(Levine et al. 2018) cancer survivors who developed nonsurgical, premature 
menopause are less likely to become pregnant (RR 0.49, 95% CI 0.27-0.80) or have a 
live birth (RR 0.42, 95% CI 0.19-0.79) between the age of 31 to 40 years compared to 
survivors without premature menopause. It is important to remember, however, 
that a woman´s fertility will decrease several years before menopause (Barton et al. 
2013); therefore, a regular menstruation cycle cannot rule out infertility in cancer 
survivors.  
 
When assessing the risk for POI, in addition to detection of menstrual cycle and 
FSH serum levels, measurement of antral follicle count (AFC) and anti-Mullerian 
hormone (AMH) is often used (Anderson et al. 2013, Dunlop et al. 2015, Freour et al. 
2017). Measurement of AFC requires a vaginal ultra-sound, performed early in the 
follicular phase by a skilled operator, whereas AMH serum levels can be measured at 
any time during the menstrual cycle (Freour et al. 2017). AMH is produced by growing 
ovarian follicles and is considered a good tool to measure ovarian reserve (Dunlop et 
al. 2015). A low AMH serum level can predict POI in adult women many years before 
actual menopause, but AMH can also be used to predict treatment-related ovarian 
damage in prepubertal childhood cancer survivors (Dunlop et al. 2015). AMH is also 
used to predict ovarian reserve and expected ovarian response before fertility 
treatments, especially in women of a higher age (Rasool et al. 2017). However, one 
study (Hagen et al. 2013) found that young, healthy women with low AMH levels had 
a similar time to pregnancy compared to those with normal AMH. Another study 
(Hamre et al. 2012) on female childhood cancer survivors found that although 44% 
of the cancer survivors had low AMH levels, 93% achieved pregnancy. AMH is 
currently considered a good tool to measure ovarian reserve, but further studies are 
needed to predicting the need for fertility treatments or fertility preservation in 
cancer survivors (Freour et al. 2017). Studies have shown measurement of AFC and 
AMH to be equally good markers on ovarian reserve (Freour et al. 2017). However, 
AMH serum levels are easier to measure than AFC, thus, it is more frequently used 
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2.5.2 FERTILITY TREATMENTS  
 
 A clinical fertility assessment is generally recommended in the absence of any 
known cause of infertility if a couple have tried to conceive over one year (National 
Institute for Health and Care Excellence 2013). An earlier assessment is 
recommended if a woman is over 35 years of age or a known cause of infertility is 
present. Persons at risk of infertility because of a planned treatment (cancer 
treatment for example) should be offered immediate referral to a specialist (National 
Institute for Health and Care Excellence 2013). 
 
According to the International Glossary on Infertility and Fertility Care, medically 
assisted reproduction (MAR) includes ovulation induction, ovarian stimulation, all 
assisted reproductive technologies (ART), uterine transplantation and intrauterine, 
intracervical and intravaginal insemination with semen of husband/partner or donor 
(Zegers-Hochschild et al. 2017). Ovulation induction (OI) is generally used in 
anovulation or oligo-ovulation with the aim to induce normal ovulatory cycles. The 
most commonly used drugs are clomiphene citrate, aromatase inhibitors and 
gonadotropins. Ovarian stimulation aims to induce the development of ovarian 
follicles and can be followed by timed intercourse or insemination, as well as ART, to 
obtain multiple oocytes at follicular aspiration. Intrauterine insemination (IUI) is a 
procedure in which laboratory-processed sperm is injected into the uterus to 
attempt a pregnancy. The most common reason for use of IUI is low semen quality, 
but it is also used in unexplained infertility. ART includes all interventions requiring 
in vitro handling of both human oocytes and sperm or of embryos for the purpose of 
reproduction. This includes, but is not limited to, in vitro fertilization (IVF), intra-
cytoplasmic sperm injection (ICSI), frozen embryo transfer (FET), embryo and oocyte 
cryopreservation or donation (International Glossary on Infertility and Fertility Care). 
 
With regard to fertility treatments, only a few studies exist that document these 
outcomes in cancer survivors. Barton et al.´s study (2013) found a 48% increased risk 
for clinical infertility in cancer survivors compared to controls. Cancer survivors 
sought medical help for their infertility as often as their siblings but were less likely 
to be prescribed fertility drugs for their condition (RR 0.57, 95% CI 0.46-9.70). Despite 
a longer time to pregnancy among cancer survivors with clinical infertility, nearly 
two-thirds of cancer survivors with infertility reported a pregnancy (Barton et al. 
2013).  
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Another study (Das et al. 2012) estimated the ovarian reserve and response to 
IVF and in vitro maturation treatment following chemotherapy. They found that 
female cancer survivors have lower peak estradiol levels on the day of human 
chorionic gonadotropin administration during fertility treatments and a lower 
number of oocytes that can be retrieved compared to healthy female controls.  A 
third study (Luke et al. 2016) investigated the likelihood of a live birth in cancer 
survivors using autologous oocytes or donor oocytes. They found that live birth rates 
after the use of donor oocytes are similar compared to healthy controls, whereas live 
birth rates after use of autologous oocytes decrease in cancer survivors compared to 
controls.  
 
Only a few published studies, mostly on breast cancer patients, are available 
concerning the safety of fertility treatments and controlled ovarian stimulation after 
cancer (Meirow et al. 2014, Oktay et al. 2015, Goldrat et al. 2015). Short-term 
exposure of high estrogen levels in ovarian stimulation during ART is a concern in 
breast cancer survivors, especially those with endocrine receptor positive tumors 
(Meirow et al. 2014). Overall survival rates and relapse of cancer were similar in 
breast cancer patients undergoing ART compared to breast cancer patients without 
fertility treatments (Goldrat et al. 2015). In the study by Goldrat et al., however, most 
fertility treatments were oocyte donations and ovulation inductions, procedures 
requiring no or very low hormonal ovarian stimulation. To avoid high estrogen levels 
during ART, alternative protocols for ovarian stimulation with co-administration of 
tamoxifen or letrozole have been developed (Meirow et al. 2014, Oktay et al. 2015). 
Pregnancy rates with these alternative protocols are similar to those of healthy 
women undergoing ART in these studies (Oktay 2015). To summarize, current limited 
data suggest that fertility treatments and controlled ovarian stimulation do not 
increase the risk for cancer recurrence (Lambertini et al. 2016).  
2.5.3 FERTILITY PRESERVATION 
 
ICMART defines fertility preservation as various interventions, procedures and 
technologies to preserve reproductive capacity (Zegers-Hochschild et al. 2017). A 
fertility preservation procedure can be performed before medical treatment that 
may cause infertility (such as radiotherapy or chemotherapy) or after cancer 
treatment, if diminished ovarian reserve is detected in a cancer survivor not ready to 
attempt pregnancy (National Cancer Institute 2018). Different fertility preservation 
options are available based on patient-related factors and cancer-treatment related 
factors. These factors include the woman´s age, whether the woman has a partner, 
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possibility to postpone cancer treatment, type of cancer treatment and the risk of 
metastasis to the ovaries (Roberts et al. 2005). 
 
Embryo and oocyte cryopreservation are the main methods of preserving fertility 
in female cancer patients (Peccatori et al. 2013). These are established fertility 
preservation methods that require the woman to go through oocyte retrieval, after 
which the embryo or oocyte is cryopreserved (Oktay et al. 2018). The success rate 
depends on the number and quality of follicles retrieved. Pregnancy rates were 
previously higher with embryo cryopreservation compared to oocyte 
cryopreservation (Kuwayama et al. 2005). However, during recent years, the 
pregnancy rates after oocyte cryopreservation have improved with results similar to 
those of embryo cryopreservation (Rienzi et al. 2012). The major limitation of these 
techniques is the delay in cancer treatment (typically 10-14 days) (Lambertini et al. 
2016). Embryo cryopreservation requires a partner or sperm donor, whereas oocyte 
cryopreservation can be performed on single women. These treatment methods can, 
however, only be used in post-pubertal women. 
 
In ovarian tissue cryopreservation, ovarian cortical tissue is obtained by surgery 
(laparoscopy or laparotomy), dissected into small fragments and cryopreserved 
(Ronn et al. 2014). After cancer treatment, the tissue can be re-transplanted into the 
pelvis or abdominal wall (Ronn et al. 2014). This technique has proven to be effective 
but it is still experimental, in contrast to embryo and oocyte cryopreservation (Loren 
et al. 2013, Anderson et al. 2015). It can be used in prepubertal girls and in adult 
women who cannot delay cancer treatment or who have already received cancer 
treatment (Lambertini et al. 2016). One concern with this technique is the potential 
reintroduction of cancer cells, especially in hematological malignancies (Lambertini 
et al. 2016). There is ongoing research on in vitro techniques that would make it 
possible to develop mature oocytes from the primordial follicle stage. This would 
enable use of cryopreserved ovarian tissue for later IVF instead of re-transplantation 
of ovarian tissue (Bertoldo et al. 2018, Fabbri et al. 2018). 
 
In addition to these, there are a number of other techniques that have been used 
with variable success (Ronn et al. 2013). Ovarian suppression with gonadotropin-
releasing hormone (GnRH) agonist treatment during chemotherapy as a method to 
maintain fertility has yielded conflicting results (Oktay et al. 2018). However, recent 
studies (Moore et al. 2015, Lambertini et al. 2015) have shown a protective effect on 
the ovaries, and one meta-analysis of breast cancer patients found a reduced risk of 
64% of treatment-related POI and an increasing possibility of 83% for pregnancy 
(Lambertini et al. 2015). The current recommendation is that ovarian suppression 
can be considered if other fertility preservation techniques are not feasible (Oktay et 
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al. 2018). Ovarian transposition (oophoropexy) indicates a surgical procedure in 
which the ovaries are moved out of the radiation field to protect the ovarian function 
in cancer patients (Lee et al. 2006). Its success rate is approximately 50% based on 
short-term menstrual function (Clough et al. 1996). However, menstrual function is 
a poor measurement of fertility and it is possible that the success rate is lower. 
Scatter radiation and reduced ovarian blood supply are believed to be the most 
common reasons for failure (Clough et al. 1996). One concern is the possibility of 
metastatic disease in the ovaries. In Morice et al.´s (2000) study of women with 
cervical cancer, a metastatic disease was found in a minority (1%) of the patients 
after ovarian transposition.   
 
International guidelines of fertility preservation in cancer patients (Lambertini et 
al. 2016, Oktay et al. 2018) recommend that clinicians should discuss the impact of 
cancer treatments on fertility with all cancer patients or their parents as early as 
possible. Furthermore, fertility preservation should be considered if the patient is 
interested in having children later on. In Finland, different cancer treatments have 
been categorized according to the risk of permanent amenorrhea (Table 2). Table 2 
is a modification of the original categorization by the American Society of Clinical 
Oncology (Lee et al. 2006). Cancer treatments with an over 80% risk for permanent 
amenorrhea are classified as having a very high risk for infertility, whereas 
treatments with a less than 20% risk for amenorrhea are classified as having a low 
risk for infertility. Treatment combinations, new cytotoxic drugs and individual 
reactions to treatments pose a challenge when evaluating the risk for infertility (Lee 
et al 2006). In Finland, fertility preservation for prepubertal girls with cancer is 
considered if the risk for infertility is very high, whereas for post-pubertal girls and 
adult women it is considered if the risk for infertility is high (Finnish National 
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Table 2 Risk of infertility according to the main cancer treatments. A modification of the 












Radiation Ovaries   <10 Gy >10 Gy  
 Spine  18-24 Gy 24-36 Gy   
 Abdomen  10-15Gy pre 
pub 
>15 Gy pre pub   





 Uterus  14-30 Gy >25 Gy pre pub 
>45 Gy post 
pub 
  
 Vagina  90-100 Gy    
 Total body   X   






 <6-9 g/m2 >6-9 g/m2   
 Busulfan   600 mg/m2   
 Melphalan     X 
 Chlorambucil     X 
 Ifosfamide  <10 g/m2 >10 g/m2  X 
 Procarbazine   X   
 Carmustine   X  X 




Cisplatin  X    
 Carboplatin  X    
Anti-
metabolites 
Methotrexate X     
 Mercaptopurine X     
 5-fluorouracil X     
Vinka-alkaloids Vincristine X     
 Vinblastine X     
Podofyllotoxine Asparginase X     
Anti-tumour 
antibiotics 
Bleomycin X     
 Dactinomycin X     
HSCT= Hematopoietic stem cell transplantation, Gy=Gray 
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2.6 PREGNANCY IN CANCER SURVIVORS 
An increasing number of women around the world are postponing their 
pregnancy to later in life (United Nations. World fertility patterns 2015). The average 
age of primiparas in Finland was 26.5 years in 1987 and 29.2 years in 2017 (Statistics 
Finland 2017). Similar trends have been reported elsewhere in developed countries 
(Matthews et al. 2014). Women older than 40 years of age have a higher risk of 
chromosomal abnormalities in offspring, miscarriage and preterm delivery than 
younger women (Fredriksen et al. 2018). Maternal obesity is also rapidly increasing 
in the western world (Hansson et al. 2016). In Finland, every third pregnant woman 
is overweight (defined as a BMI over 25 kg/m2), and 13% are obese (defined as a 
BMI over 30 kg/m2) (Rönö et al. 2014).  Overweight women have an increased risk 
for gestational diabetes mellitus (GDM) and pre-eclampsia as well as an increased 
risk for cesarean section (CS) and postpartum infections (Athukorala et al. 2010). 
These two factors are a challenge for obstetricians today. 
 
Preterm delivery is defined as a delivery before week 37 of gestation. In Europe, 
75% of all neonatal deaths occur in infants born preterm (Chang et al. 2013). 
Incidence rates for preterm delivery vary among the European countries, 
representing 5-10% of all live births (Chang et al. 2013). Preterm deliveries can be 
sub-classified into two groups: spontaneous preterm deliveries and preterm 
deliveries due to maternal pregnancy-related conditions, necessitating medically 
induced preterm delivery (Goldenberg et al. 2008, Menon et al. 2010). Many studies 
have consistently showed that the risk for preterm delivery is elevated among cancer 
survivors compared to siblings and healthy controls (Table 3); however, the reasons 
behind the preterm deliveries are unclear. Some studies have found the risk to be 
associated with abdominal radiotherapy (Green et al. 2010, Signorello et al. 2006). In 
childhood and adolescent cancer patients, abdominal irradiation could lead to a 
reduced uterine volume and blood flow (Larsen et al. 2004), resulting in uterine 
fibrosis and cervical shortening. This, in turn, could lead to premature contractions 
and rupture of the amniotic membranes during pregnancy, both of which are risk 
factors for spontaneous preterm delivery (Menon et al. 2010). However, 
chemotherapy has also been associated with preterm delivery (Madanat-Harjuoja et 
al. 2010, Anderson et al, 2017). Here, a different mechanism must be responsible. 
One explanation could be maternal pregnancy-related conditions that might 
necessitate medically induced preterm deliveries. The most common conditions are 
pre-eclampsia, GDM and placental pathologies (Ananth et al. 2006).  
 
Regarding possible conditions that explain spontaneous preterm delivery in 
cancer survivors, only a few studies are available, and those mostly studied 
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premature rupture of the amniotic membranes (Clark et al. 2007, Reulen et al. 2017, 
Haggar et al. 2014); one included threatened preterm labor (Haggar et al. 2014). 
None of these studies found an increased risk for either of these outcomes. 
Concerning maternal pregnancy-related conditions, that could possibly lead to 
medically induced preterm delivery in cancer survivors, an Australian study (Haggar 
et al. 2014) found an increased risk for pre-eclampsia (RR 1.32, 95% CI 1.04–1.87) 
and GDM (RR 2.65, 2.08–3.57). These results were confirmed in a British study 
(Reulen et al. 2017) in which  survivors of Wilms tumor treated with abdominal 
radiotherapy had over a threefold risk for the development of hypertension (RR 3.29, 
2.29-4.71) and GDM (RR 3.35, 1.41-7.93) during pregnancy. Only one study (Haggar 
et al. 2014) on placental pathology in cancer survivors was found, which showed no 
increased risk for retained placenta. Placental pathologies increase the risk not only 
for postpartum hemorrhage, one of the leading causes for maternal mortality, but 
also preterm delivery (Campbell et al. 2006), making it an important target to study. 
Green et al.´s study (2010) evaluated the occurrence of malpresentation of the fetus 
(a common reason for elective CS) and found that the risk for malpresentation of the 
fetus increased with increasing dose of abdominal radiation. 
 
Cancer survivors, especially those treated with anthracyclins or chest irradiation, 
have an increased risk of cardiac abnormality later in life (Lipshultz et al. 2006, 
Armenian et al. 2015). The physical stress of a pregnancy could trigger 
cardiomyopathy or pulmonary hypertension, originally caused by the cancer 
treatment (Lipshultz 2006). Hines et al.´s retrospective cohort study (2016) evaluated 
pregnancy-associated cardiomyopathy and found that cardiomyopathy occurred 
rarely (0.3%) in pregnant cancer survivors, but an increased risk was observed among 
those treated with anthracyclins. Accordingly, surveillance for cardiomyopathy is 
recommended before pregnancy or during the first trimester for all cancer survivors 
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2.7 DELIVERY IN CANCER SURVIVORS 
Cesarean section (CS) rates are increasing worldwide. Awareness has been raised 
during the last decade about the risks that accompany CS, and attempts have been 
made to decrease these rates (WHO statement on cesarean section rates 2015). A CS 
can be life-saving in certain medical indications, such as in pre-eclampsia, placenta 
praevia, transverse lie of the fetus or asphyxia of the fetus (Hannah et al. 2000). 
However, the main reason for the increased CS rates is believed to be CS being 
performed without medical reasons on the mother´s request (Betran et al. 2018). 
The WHO has recommended a CS rate between 10 and 15%, based on CS rates in 
countries with the lowest maternal and perinatal mortality rate (Betran et al. 2015). 
The CS rate in Finland was 16.7% in 2017 (Statistics Finland 2017), which is low 
compared to other developed countries. Insufficient data exists on why certain 
women would opt for CS without a medical reason (Betran et al. 2018). Fear of 
childbirth (Nieminen et al. 2017), need for control and cultural acceptance regarding 
CS might play a role (Betran et al. 2018). Potential risk factors associated with CS 
include intrapartum and postpartum hemorrhage of the mother, infections and 
problems in subsequent pregnancies (including placental pathologies and uterine 
scar rupture) (Boerma et al. 2018). Differences in neonatal physiology following 
vaginal delivery and CS delivery are also believed to have a negative effect on the 
fetus after CS (Betran et al. 2018). 
 
Rates of induction of labor are increasing in the western world, ranging from 20% 
to 30% (Zeitlin et al. 2013). The most common indication for induction of labor is 
post-term pregnancies (more than 41 weeks of gestational age), where induction of 
labor has been shown to decrease perinatal mortality (Gulmezoglu et al. 2012). 
Induction of labor is also used in maternal pregnancy-related conditions that 
necessitate delivery (pre-eclampsia, GDM, premature rupture of the amniotic 
membranes, to name a few) or in fetal-related conditions (growth restriction or 
intrapartum infections) (Boulvain et al. 2001). However, the decision to induce a 
labor should be carefully considered as some studies indicate that induction of labor 
is associated with an increased risk for CS by up to 37% (Vrouenraets et al. 2005, Kruit 
et al. 2015). 
 
Many studies have evaluated the risk for CS in cancer survivors. All except one (Table 
3) show an elevated risk for CS in general or elective CS with RRs of 1.1-2.6. One study 
(van der Kooi et al. 2018), however, observed that in survivors with a more recent 
cancer diagnosis, the risk for CS approached rates in controls. Two studies (Clark et 
al. 2007, van der Kooi et al. 2018) evaluated the risk for assisted vaginal delivery 
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(breech delivery or delivery with vacuum extraction/forceps) and found a small but 
significant increased risk in cancer survivors compared to female controls. Conflicting 
results are reported regarding the risk of postpartum hemorrhage in cancer 
survivors. Some studies found no increased risk (Haggar et al. 2014, Reulen et al. 
2017), whereas one study (van der Kooi et al. 2018) found an overall increased risk 
(RR 1.42, 1.29–1.55), that, however, approached rates in controls during the most 
recent time period. Only one study on induction of labor was found (Clark et al. 2007) 
with no elevated risk.  
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 AIMS OF THE STUDY 
This study focused on the reproductive health of female early onset cancer survivors 
by using registry data. The present investigation assessed fertility treatments, 
pregnancy-related conditions and adverse obstetric outcomes in this group of 
survivors. The following specific aims were addressed: 
 
1. To study the use of fertility drugs in female cancer survivors. 
 
2. To identify the associations of cancer characteristics and fertility treatments in 
female cancer survivors giving birth. 
 
3. To identify pregnancy-related conditions and risk factors for preterm delivery in 
female cancer survivors. 
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 MATERIALS AND METHODS 
This study was based on a cohort of Finnish female cancer survivors diagnosed with 
cancer between 1953 and 2004 at the age of 0-34 years (Study II and IV) and cancer 
survivors diagnosed between 1953 and 2012 at the age of 0-39 years (Study I and III). 
4.1 REGISTERS 
4.1.1 THE CENTRAL POPULATION REGISTER (CPR) 
 
Since 1967, each person being born or permanently living in Finland is assigned a 
personal identity code (PIC) that allows individual linkage between different registers 
and databases. The Central Population Register (CPR), founded in 1969, is nationwide 
and covers all Finnish residents. The CPR includes basic personal information (such 
as PIC, name, address, residential history, family relations, death or emigration). 
Individuals born in 1955 or later can reliably be linked to their parents, and offspring. 
While all children of a parent are listed, siblings of cancer survivors can be identified. 
4.1.2 THE FINNISH CANCER REGISTRY (FCR) 
 
The nationwide Finnish Cancer Registry (FCR), founded in 1952, began 
registration one year later, in 1953. In 1961, the National Board of Health made it 
compulsory to report all cancer cases diagnosed in the Finnish health-care system. 
The clinical information is usually reported by the physician treating the patient and 
the histologic data by the department of pathology. In addition to these, Statistics 
Finland reports information on death certificates concerning malignancies directly to 
FCR. Thus, the data in this nationwide cancer register covers 96% of solid tumors and 
86% of hematologic malignancies. Of all cancers, 93% were morphologically verified 
(Leinonen et al. 2017). According to tumor behavior, cancer cases are divided into 
four different groups: benign, semi-malignant, in-situ and invasive cancers. All benign 
and semi-malignant tumors, except those of the central nervous system (CNS), were 
excluded in this thesis. Benign and semi-malignant CNS tumors were included, as 
their treatment is similar to that of malignant CNS tumors. This thesis also excluded 
in-situ cancers. Other data recorded in the FCR include anatomical site, histology, 
treatment (radiotherapy, chemotherapy, surgery and hormonal) and time of 
diagnosis. 
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4.1.3 THE MEDICAL BIRTH REGISTER (MBR) 
 
The Medical Birth Register (MBR) was established in 1987 and contains 
information on nearly all live births and stillbirths with a birth weight of more than 
500g or a pregnancy duration of at least 22 weeks. Data is compiled at the delivery 
hospital, using the maternity records. Missing information is completed by using data 
compiled by the Population Register Center and Statistics Finland that provide 
information on births outside the hospital, as well as stillbirths and deaths during the 
first week of life (Gissler et al. 2004). This way, less than 0.1% of infants are missing 
from the MBR (Gissler et al. 2002). In addition, the MBR contains detailed 
information on pregnancy-related conditions. Reforms of the MBR were made during 
1990 and 2004, both times adding more important outcomes to follow. ICD-10 
diagnostic codes from the maternity records are included in the MBR from 2004 
onwards. 
4.1.4 REIMBURSEMENT REGISTER FOR PRESCRIBED MEDICINES (RPM) 
 
Study I investigated fertility treatments in female cancer survivors and their 
siblings based on fertility drug prescription. That study used information from the 
Reimbursement Register for Prescribed Medicines (RPM), in addition to previously 
mentioned studies. The RPM is controlled by the Social Insurance Institution (SII) and 
started to register purchased prescription drugs in 1993. The register is complete 
from 1995 onwards and includes all purchased, reimbursed prescription drugs. Over-
the-counter drugs and drugs received in hospital care are not included. This database 
includes the patients´ PIC, drug substance, purchase date, amount delivered, 
package size and price of the medication. Drugs are coded according to the specific 
categories of the Anatomical Therapeutic Chemical (ATC) codes released by the 
WHO. A study comparing data on fertility drug purchase from RPM and aggregated 
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4.2 STUDY POPULATION 
This thesis evaluated three different female cancer patients/survivors cohorts 
(Table 4). Cancer survivors were compared to half and full siblings in three of the 
studies (Studies I, II, IV). Study III compared cancer survivors to five age-matched 
female comparison subjects per case. 
4.2.1 STUDY I 
 
Study I identified 23,125 female cancer survivors from the FCR who were diagnosed 
with cancer between January 1953 and December 2012, at 0-39 years of age (Figure 
6). The study identified 20,542 female siblings without cancer before 16 years of age 
by linkage to the CPR. It identified 16,640 survivors and 18,184 siblings without 
deliveries before possible drug purchase between 1993 and 2012 by further linkage 
to MBR and RPM. The study included only women who were in the age range of 16-
41 years between 1993 and 2012, wich left us with 8,929 survivors and their 9,495 
siblings. The fertility drug purchase was the primary outcome during this time period 
and age range, whereas pregnancies greater than 22 gestational weeks, death, 
emigration or cancer diagnosis in the sibling-group were secondary outcomes. Those 
with a notification of aromatase inhibitor medication as a long-term cancer 
treatment (used in breast cancer) were excluded from the follow up. Altogether, the 




Table 4 Description of data obtained from the different outcome registers for studies I-IV. 
FCR= Finnish cancer register, CPR= Central population register, MBR= Medical Birth 
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Main cohort for studies I and III, female cancer patients 
                    Age 0-39 years, diagnosed 1953-2012 
       Study I (N=23,125)                                              Study III (N=24,610) 
Female comparisons, 
without early onset cancer 
N=121,353 
Female siblings, without 
cancer before 16 years 
N=20,542 
Linkage to CPR 
Linkage to MBR 
and RPM 
Females without deliveries before 




Females at the age of 16-41 years 





















Females with deliveries between 1991 and 
2013 
Survivors N=8,097/ Offspring N=15,900 








offspring born before 
or less than 9 
months after cancer 
diagnosis 
N=10,823 
Exclude if multiparous 
or without matched 
control 




Exclude if multiple 
birth 




Figure 6 Characteristics of data collection for Study I and Study III 




















































Main cohort for studies II and IV 
Female cancer patients  
Age 0-34 years, diagnosed 1953-2004 
N=13,799 








Female cancer survivors with 
deliveries between 1987 and 2013 
N=4,105 
Offspring N=7,983 
Female siblings with deliveries 
between 1987 and 2013 
N=9,533 
Offspring N=20,692 
Female cancer survivors 
N=2,401 
Offspring N=4,807 
Exclude births before or 




1,800 survivors with first deliveries 
Study IV 







1,281 female cancer survivors 
(1,974 deliveries) 







Exclude twin and triplet deliveries 
d






Exclude if multiparas 
Figure 7 Characteristics of data collection for Study II and Study IV  
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4.2.2 STUDIES II AND IV 
 
We identified 13,799 female cancer patients from the FCR, diagnosed between 
January 1953 and December 2004 at 0-34 years of age (Figure 7). We used the PIC to 
identify 21,323 siblings of cancer patients from the CPR. By linking these two cohorts 
to the MBR, we identified 2,401 cancer survivors (excluding those who were 
pregnant during cancer treatment) and 9,533 siblings with deliveries between 
January 1987 and December 2013. Information on overall fertility treatments were 
available from January 1991 onwards and the fertility treatments were even further 
sub-categorized from January 2004 onwards. As we wanted to evaluate different 
types of fertility treatments in Study II, we excluded women giving birth before 
January 2004, which left us with 1,281 survivors with 1,974 deliveries and 3,509 
siblings with 6,107 deliveries. We also present new, unpublished results in this thesis 
on fertility treatments among cancer survivors and their siblings giving birth between 
January 1991 and December 2013 (2,230 survivors with 4.282 deliveries and 8,185 
siblings with 16,787 deliveries). 
 
Study IV used the same study population as in Study II, with some exceptions; 
only first, singleton pregnancies were included but for a longer time period, between 
1987 and 2013, than in Study II (Figure 7). This left us with 1,800 deliveries of cancer 
survivors and 7,137 deliveries of siblings. 
4.2.3 STUDY III 
 
We identified 24,610 female cancer patients alive at 16 years of age from the FCR. 
These cancer patients were diagnosed between January 1953 and December 2012, 
at 0-39 years of age (Figure 6). We sampled five age-matched female comparison 
subjects for every cancer patient. We received information about pregnancy-
related conditions, as well as the deliveries, by linking these two cohorts to the 
MBR. This study also excluded deliveries occurring before or less than 9 months 
after cancer diagnosis (10,823 deliveries). We wanted to avoid the possible 
influence that a previous pregnancy history or a multiple birth might have on the 
outcomes studied, so we included only first, singleton pregnancies in this study. 
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4.3 METHODS 
In all our studies, cancer survivors were sub-categorized according to cancer type 
based on the International Classification of Childhood Cancer (ICCC3) (Steliarova-
Foucher et al. 2005), primary cancer treatment, time from diagnosis to fertility drug 
purchase/delivery and diagnostic age (Table 5). In addition, Study I used information 
on calendar time period at possible fertility drug purchase and attained age of the 
women. Studies II, III and IV used information on maternal age at delivery, maternal 
smoking, gestational age and year of delivery (Table 6). The follow up for cancer 
survivors, siblings and comparison controls started from 16 years of age in all our 
studies. 
 








Age at diagnosis (years) 0-14 (childhood) 
 15-24 (adolescents) 
 25(-34)-39 (young adults) 
Cancer treatment Chemotherapy 
 Radiotherapy 
 Surgery, only 
 Missing 
Cancer type (ICCC3) Leukemia 
 Lymphoma 
 CNS 
 Sympathetic Nervous System 
 Retinoblastoma 
 Renal Tumors 
 Hepatic Tumors 
 Malignant bone Tumors 
 Soft tissue and other Sarcomas 
 Germ cell, Gonadal and Trophoblastic neoplasms 
 Carcinomas and other malignant epithelial 
neoplasms 
 Others 
Time from diagnosis to fertility drug 
purchase/delivery (years) 
Study I Study II Study III Study IV 
 0-2 0-5 0-5 0-1 
 3-5 6-10 6-10 2-5 
 6-10 11-15 11-38 6-10 
 11-41 16-25  11-34 
  26-34   
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Table 6 Descriptive characteristics of the women, used in this thesis 
 
4.3.1 STUDY I 
 
To identify fertility treatments in female cancer survivors and their siblings, we 
performed a linkage to the RPM. Fertility drugs prescribed to these women during 
1993-2012 were analyzed and used as a proxy for use of fertility treatments. The 
main outcome was overall fertility treatment, which was further sub-classified into 
Study I 










Time period of delivery Study II Study III Study IV 
 2004-2008 1991-2002 1987-1989 
 2009-2013 2003-2013 1990-1999 
  2000-2009 
  2010-2013 
Age at delivery (years) <25 
 25-29 
 30-34 
 35 or more 
Maternal smoking No 
 Yes 
 Missing 
Infant sex Male 
 Female 
Gestational age <32 (very preterm delivery) 
 32-36 (preterm delivery) 
 37-41 (full term delivery) 
 42 or more (post term delivery) 
 Missing 




 4500 or more 
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OI (including IUI) and ART (including in vitro fertilization, intracytoplasmic sperm 
injection and frozen embryo transfer).  
 
We used information on fertility drug purchases during the following 21 days 
after the initial fertility drug purchase to sub-classify fertility treatments as either OI 
or ART. A fertility treatment was classified as an OI if clomiphene citrate or an 
aromatase inhibitor alone was used without the combination of any other fertility 
drug during the following 21 days. The treatment was also classified as an OI if a 
gonadotropin was used without use of GnRH analogues. A fertility treatment was 
classified as an ART if a GnRH agonist or GnRH antagonist was the first drug used. 
Gonadotropin use in combination with GnRH analogues was also classified as ART. In 
this data, four survivors were excluded from the follow up after a notification of 
fertility drug purchase but before being categorized into the OI or ART treatment 
group. Two siblings were included in the follow up after categorization into the any 
treatment group but before categorization into the OI or ART treatment group (as 
their matched survivor received a cancer diagnosis after the sibling’s initial fertility 
drug purchase). This explains why the numbers in the OI and ART treatment groups 
do not always add up to the numbers in the any treatment group (Table 8). 
4.3.2 STUDY II 
 
To investigate fertility treatments in cancer survivors and siblings leading to 
delivery, we gathered information on fertility treatments from the MBR. In the MBR, 
information on fertility treatments is based on self-report of the mother and her 
maternity records. Overall fertility treatments are available from 1991 onwards and 
sub-classified into OI (including IUI) and ART (including IVF, ICSI and FET). IUI is 
reported as a separate group from 2004 onwards, enabling classification of fertility 
treatments into three sub-groups: OI, IUI and ART.  
4.3.3 STUDY III 
 
Study III compared maternal pregnancy-related conditions in cancer survivors 
and matched comparison subjects. Pregnancy-related outcomes found in the MBR 
were either available since 1991 (any hospitalization, which was subclassified into 
hospitalization due to threatened preterm labor, vaginal bleeding and pre-eclampsia, 
as well as malpresentation and placental pathologies) or 2004 (premature rupture of 
the amniotic membranes, use of low molecular weight heparin (LMWH) for 
prevention of deep vein thrombosis (DVT), GDM, intrahepatic cholestasis (IHC), fear 
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of childbirth, diseases of the circulatory system and mental disorders and diseases of 
the nervous system complicating pregnancy and childbirth). In this study, some of 
the outcomes were based on dichotomous variables (hospitalization due to different 
reasons, use of LMWH and GDM), whereas others were based on ICD-10 codes: 
premature rupture of the membranes (ICD-10 O42.0, O42.1, O42.2 and O42.9), IHC 
(O26.6), fear of childbirth (O99.80), diseases of the circulatory system (O99.4) and 
mental disorders and diseases of the nervous system (O99.3). Pre-eclampsia was 
defined as a blood pressure of 140/90 or more after 20 weeks of gestation in a 
woman with previous normal blood pressures. One of the following was additionally 
required: proteinuria, thrombocytopenia, renal insufficiency, impaired liver function, 
pulmonary edema or cerebral/visual symptoms. GDM was defined as a pathological 
2-hour, 75 g oral glucose tolerance test. Placental pathologies included placenta 
praevia, placental abruption and manual removal of the placenta. IHC is a pregnancy-
specific liver disease characterized by raised serum bile acids and maternal itching of 
the hands and feet. IHC is proposed to be associated with an increased risk for fetal 
distress and stillbirth, which is why an induction of labor or elective CS is usually 
recommended at the latest when the pregnancy is full term (Geenes et al. 2014). 
4.3.4 STUDY IV 
 
    To identify adverse obstetric outcomes in cancer survivors and their siblings, the 
two cohorts were linked to the MBR. Information on mode of delivery (spontaneous 
vaginal delivery, instrumental vaginal delivery and overall CS), induction of labor and 
medical pain relief was available from 1987 onwards. In 1991 CS were further sub-
classified into elective (planned) cesarean delivery and urgent cesarean delivery 
(when there is or might be a threat to the fetus or the mother and the time between 
the decision to operate and the birth of the fetus should not exceed 30 minutes). 
From 2004 onwards emergency CS (where the time between decision to operate and 
the birth of the fetus should not exceed 10 minutes) was also included. Information 
on prolonged labor (ICD-10 O63.0), anal sphincter injury (ICD-10 O70.2, O70.3 and 
O70.4) and postpartum hemorrhage was available from 2004 onwards. Asphyxia of 
the fetus was analyzed from 1991 onwards and defined as pathological changes in 
the heart rate of the fetus (based on cardiotocography), a scalp blood-pH below 7.05 
during delivery or use of ICD-10 code O68 (labor and delivery complicated by 
abnormality of fetal acid-base balance) or P20 (intrauterine hypoxia). Most 
outcomes, except prolonged labor and anal sphincter injury, were based on 
dichotomous variables in the MBR. Induction of labor was performed either by 
intravaginal or oral administration of misoprostol, dilatation of the cervix by a balloon 
catheter, intravenous administration of oxytocin or mechanical rupture of the 
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amniotic membranes. Postpartum hemorrhage was defined as more than a 1,000 ml 
blood loss during the first 24 hours after delivery. 
4.4 STATISTICAL ANALYSES 
In Study I, we calculated incidence rate ratio (IRR), whereas in Studies II, III and 
IV, we calculated odds ratios (ORs) with 95% confidence intervals (CI) for 
dichotomous outcomes. In rare events (incidence being less than 10%), as is mostly 
the case in outcomes studied in this thesis, ORs provide a reasonable approximation 
of the risk (Davies et al. 1998), which is why the term increased/decreased risk is used 
for statistically significant ORs. It is notable, however, that ORs present associations 
of increased/decreased risks rather than confirmed causality between exposure and 
outcome. Level of statistical significance was set at p < 0.05 in all the primary 
analyses. 
4.4.1 STUDY I 
 
Study I reports incidence rates of fertility treatments (the number of events per 
10,000 person years) and conditional probability of fertility treatment by time 
period and age of the women. We used the Poisson regression model to calculate 
IRRs of fertility treatments in cancer survivors and siblings, adjusting for age and 
calendar time at possible drug purchase. We calculated an overall IRR, assuming no 
heterogeneity by age and calendar time period. In additional analyses, we report 
relative excess risks for fertility treatments, compared to a baseline IRR (age 20-24, 
time period 1993-1997), allowing heterogeneity. We used a likelihood ratio test to 
calculate the statistical significance of the heterogeneity. Using generalized additive 
models (Wood et al. 2006), we plotted smoothed incidence rates of any fertility 
treatments by age and time period of fertility drug purchase. All analyses were 
carried out using R version 3.5.1. 
4.4.2 STUDIES II AND IV 
 
Studies II and IV used univariate and multivariate unconditional logistic regression 
models to estimate ORs with 95% CIs for dichotomous outcomes, comparing 
survivors to siblings. We did not perform direct matching of cancer survivors to their 
siblings (allowing conditional logistic regression models), as it would have diminished 
the sample to 12% of the entire data available. We performed multivariate 
subanalyses stratifying by age at cancer diagnosis, cancer treatment, elapsed time 
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from diagnosis to delivery and cancer type in order to study possible patient-related 
risk factors. These analyses used Bonferroni correction to take multiple comparisons 
into account. We analyzed differences in categorical variables between survivors and 
siblings by using the χ2-test. Statistical analyses in these two studies were computed 
by using STATA version 12.1 (StataCorp, College Station, TX). 
 
Study II included multiple pregnancies of the same mother. We used random 
effects modeling to account for this. In the final analyses, we adjusted for maternal 
age at delivery, time period of delivery, smoking and parity. In study IV we considered 
potential confounders to be maternal age at delivery, time period of delivery, 
gestational age, birth weight, maternal smoking, socioeconomic status, 
malpresentation and placental pathologies. To identify variables to be included in the 
final model, a likelihood ratio test was used. In the final analyses, we adjusted for 
maternal age at delivery, time period of delivery, gestational age and smoking. 
4.4.3 STUDY III 
 
Study III sampled five age-matched comparison subjects for every cancer 
survivor. We performed direct matching, allowing us to use conditional logistic 
regression models to estimate ORs and 95% CIs for outcomes categorized as 
dichotomous variables. In the final model, we adjusted for maternal age at delivery, 
gestational age and maternal smoking. We compared pregnancy-related conditions 
in preterm (less than 37 gestational weeks) and term pregnancies (37-41 gestational 
weeks), adjusting for early onset cancer (in addition to maternal age at delivery and 
maternal smoking) to find explanations for the increased risk of preterm deliveries in 
cancer survivors. To study whether survivors with a certain pregnancy related 
outcome had an excess risk of preterm delivery compared to corresponding 
comparison subjects, we included interactions and tested their significance using 
likelihood ratio tests. 
 
As in Studies II and IV, we performed subanalyses, stratifying by age at cancer 
diagnosis, cancer treatment, elapsed time from diagnosis to delivery and cancer type. 
In this study also, 95% CIs were corrected for multiple comparison with the 
Bonferroni correction. We analyzed differences between survivors and comparison 
subjects in categorical variables using the χ 2-test and computed statistical analyses 
with STATA 14.0. 
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4.5 ETHICS 
The study protocol for Study II, III and IV, including the use of administrative 
health data, was approved by the National Institute for Health and Welfare (Dnr 
THL/1/5.05.00/2014) and included an evaluation from the ethical committee. In 
addition, Study I was also approved by the SII (Dnr KELA/69/522/2014). The research 




5.1 FERTILITY TREATMENTS (STUDIES I AND II) 
The overall use of fertility drugs between 1993 and 2012 was increased in cancer 
survivors compared to siblings (Study I). Altogether, 6.1% of female cancer survivors 
and 3.8% of female siblings used fertility drugs (IRR 1.43, 95% CI 1.25-1.65). In Study 
II the overall use of fertility treatments between 1991 and 2013 (unpublished results) 
was in line with the results in Study I (OR 1.48, 95% CI 1.00-2.17) as 3.7% of female 
cancer survivors giving birth used fertility treatments compared to 1.9% of the 
female siblings. As for survivors and siblings giving birth between 2004 and 2013, 
5.2% of survivors and 2.8% of siblings used fertility treatments (OR 1.84, 95% CI 1.18-
2.86). It is notable that we calculated IRRs in Study I, whereas we calculated ORs in 
Study II (Table 7). 
 
Table 7 Adjusted incidence rate ratios and odds ratios for different fertility treatments 
between 1993 and 2012 (Study I) and between 1991 and 2013 (Study II, unpublished 
results) among women with a history of cancer compared to female siblings. 
 
Study I Use of fertility drugs in cancer survivors 






Fertility treatment 541 (6.06) 358 (3.77) 1.43 (1.25-1.65) 
Ovulation induction 189 (2.12) 219 (2.31) 0.83 (0.68-1.02) 
ART 348 (3.90) 141 (1.48) 2.41 (1.97-2.96) 
Study II Fertility treatments among cancer survivors giving birth 
Outcome 1991-2013 Deliveries of survivors 
N=4,282 
N (%) 






Fertility treatment 157 (3.67) 313 (1.86) 1.48 (1.00-2.17) 
Other fertility treatments 84 (1.96) 174 (1.04) 1.49 (0.96-2.29) 
ART 116 (2.71) 250 (1.49) 1.28 (0.83-1.96) 
 
IRR, incidence rate ratio; OR, odds ratio; CI, confidence interval; ART, assisted reproductive 
technology 
1 Adjusted for age of the woman and year of fertility drug purchase 
2 Adjusted for maternal age, year of delivery, parity and maternal smoking  




5.1.1 USE OF FERTILITY DRUGS IN CANCER SURVIVORS (STUDY I) 
 
Table 8 reports use of fertility drugs according to cancer type in Study I. Cancer types 
with the highest use of fertility drugs were breast cancer (15.8%), unspecified cancers 
(8.6%), retinoblastomas (6.5%), lymphomas (6.4%) and thyroid cancer (5.4%).  
 
 
Table 8 Use of fertility drugs according to cancer type (Study I) 
 













Leukemia 688 (7.71) 22 (3.20) 1 12 (1.74) 9 (1.31) 
Lymphoma 1161 (13.00) 74 (6.37) 1 24 (2.07) 49 (4.22) 
Central Nervous System 970 (10.86) 30 (3.09) 17 (1.75) 13 (1.34) 
Sympathetic Nervous System 77 (0.86) 1 (1.30) 1 (1.30) 0 (0.00) 
Retinoblastoma 31 (0.35) 2 (6.45) 1 (3.23) 1 (3.23) 
Renal Tumors 154 (1.72) 5 (3.25) 3 (1.95) 2 (1.30) 
Malignant bone Tumors 140 (1.57) 7 (5.00) 5 (3.57) 2 (1.43) 
Soft Tissue and other Sarcomas 338 (3.79) 13 (3.85) 7 (2.07) 6 (1.78) 
Germ cell, Gonadal and 
Trophoblastic neoplasms 
523 (5.86) 14 (2.68) 8 (1.53) 6 (1.15) 
Carcinomas and other 
malignant epithelial neoplasms 
4517 (50.59) 355 (7.86) 1 101 (2.24) 253 (5.60) 
                      Digestive system 532 (5.96) 23 (4.32) 16 (3.01) 7 (1.32) 
                      Breast 1402 (15.70) 221 (15.76) 24 (1.71) 196 (13.98) 
                      Melanoma of the skin 705 (7.90) 33 (4.68) 19 (2.70) 14 (1.99) 
                      Thyroid gland 982 (11.00) 53 (5.40) 27 (2.75) 26 (2.65) 
                      Others 896 (10.03) 25 (2.79) 15 (1.67) 10 (1.11) 
        Unspecified 93 (1.04) 8 (8.60) 5 (5.38) 3 (3.23) 
         Missing 215 (2.41) 10 (4.65) 1 5 (2.33) 4 (1.86) 
 
OI, Ovulation induction; ART, assisted reproduction technology 
1 Four survivors were censored after being categorized into the any treatment group, but 







Cancer survivors had an increased use of overall fertility treatments and ART 
compared to siblings (Study I, Table 9). Allowing heterogeneity in IRR between age-
groups and time period, the IRR in any fertility treatments and ART was higher from 
2003 onwards. For example, IRR for use of ART in survivors compared to siblings was 
3.4-fold (95% CI 1.79-6.41) in 2003-2007 compared to that in 1993-1997. Regarding 
the effect of age at possible fertility drug purchase, a smaller IRR for use of ART 
among survivors older than 30 years was found compared to survivors aged 20-24 
years (Table 9). 
 
 
Table 9 Adjusted overall incidence rate ratios (IRRs) for different fertility treatments 
between 1993 and 2012 among female cancer survivors compared to their siblings. 
 
 Any treatment OI ART 
Assuming no heterogeneity in IRR by age and time period 
Overall IRR1 1.43 (1.25-1.65) 0.83 (0.68-1.02) 2.41 (1.97-2.96) 
    
Allowing heterogeneity in IRR by age and time period 
Baseline IRR1 
(age 20-24, period 1993-1997) 
1.32 (0.75-2.30) 0.60 (0.25-1.42) 2.28 (0.92-5.68) 
Relative excess risk compared to baseline IRR 
Age 16-19 - - - 
 20-24 1 1 1 
 25-29 0.66 (0.38-1.16) 1.69 (0.67-4.28) 0.62 (0.25-1.56) 
 30-34 0.86 (0.48-1.54) 1.64 (0.67-4.04) 0.41 (0.17-0.97) 
 35-41 0.59 (0.34-1.02) 1.14 (0.46-2.83) 0.35 (0.15-0.82) 
Test for heterogeneity p-value < 0.001 p-value = 0.474 p-value < 0.001 
    
Period 1993-1997 1 1 1 
 1998-2002 1.24 (0.81-1.89) 0.91 (0.52-1.59) 1.73 (0.88-3.39) 
 2003-2007 2.31 (1.53-3.49) 1.01 (0.55-1.87) 3.39 (1.79-6.41) 
 2008-2012 1.73 (1.18-2.53) 0.89 (0.53-1.50) 2.65 (1.44-4.89) 
Test for heterogeneity p-value <0.001 p-value = 0.959 p-value < 0.001 
 
IRR, incidence rate ratio; CI, confidence interval; OI, Ovulation induction; ART, Assisted 
reproductive technology 
1Adjusted for calendar period and attained age 
Statistically significant incidence rate ratios are presented in bold font (p<0.05) 
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 Figure 8 plots incidence rates/10,000 person years for overall fertility treatments 
against age at fertility drug purchase in four different time periods. Table 10 presents 
incidence rates for fertility treatments, which were quite similar in cancer survivors 
and siblings in 1993-1997. In 1998-2002, higher incidence rates for fertility 
treatments in survivors than in siblings were observed below the age of 30 years. In 
2003-2007, the difference in incidence rates for fertility treatments became 
statistically significant and was at its highest. The biggest difference in incidence rates 
was seen among women younger than 25 years of age (62/10,000 person years in 
survivors compared to 15/10,000 person years in siblings). The gap between the 
incidence rates decreased in 2008-2012, being still higher among survivors compared 
to siblings in all age groups. The highest difference was among women younger than 
25 years of age (51/10,000 person years in survivors compared to 17/10,000 person 
years in siblings). Regarding incidence rates for ART in survivors and siblings, the 
results were similar to that of overall fertility treatments. The original publication 





















































































































































































































































































   

































































































































































































































































































































































































































































































































































































































































































































5.1.2 FERTILITY TREATMENTS IN CANCER SURVIVORS GIVING BIRTH (STUDY II) 
 
Study II shows that the survivors giving birth were older than siblings (mean age 
31.5 years and 30.1 years, respectively) (p-value<0.001), and survivors were more 
likely to be primiparous (p-value<0.001). Regarding the age at cancer diagnosis and 
its association with fertility treatments in cancer survivors giving birth between 1991 
and 2013, we found a non-significant tendency for more advanced fertility 
treatments among cancer survivors treated as young adults (25-34 years of age) 
compared to siblings (unpublished results, Table 11). Similar results were observed 
among cancer survivors giving birth between 2004 and 2013, where survivors, 
treated as young adults, had an increased use of fertility treatments (OR 2.31, 95% 
CI 1.01-5.32) and ART (OR 3.13, 95% CI 1.03-9.52) compared to siblings. On the 
contrary, childhood cancer survivors, giving birth in 2004-2013, had the lowest risk 
for fertility treatments (OR 1.56, 95% CI 0.68-3.61) but an increased risk for IUI (OR 
3.42, 95% CI 1.08-10.82) compared to siblings. Note that some women (Table 11) 
underwent several different fertility treatments before becoming pregnant, which is 
why the numbers in the different treatment categories do not add up to the numbers 
in the overall fertility treatment-group.   
 
 
Table 11 Adjusted odds ratios for fertility treatments between 1991 and 2013 among 
survivors in respective diagnostic age group, compared with siblings (unpublished results). 
 
Outcome1 Age at diagnosis 
 Deliveries of 
siblings 
(N=16,787) 
n           OR 




     n                OR 




       n              OR 




     n                 OR 
















































OR, odds ratio; CI, confidence interval 
1Adjusted for maternal age, year of delivery, parity and maternal smoking 




    Time elapsed between cancer diagnosis and delivery played a central role among 
cancer survivors giving birth between 1991 and 2013 (unpublished results). We 
observed that the odds for fertility treatments increased over time, being lowest less 
than six years from treatment and highest 11-34 years from cancer treatments 
concerning both ART and other fertility treatments (Table 12). Similar results were 
observed among cancer survivors giving birth between 2004 and 2013. 
 
 
   Table 12 Adjusted odds ratios for fertility treatments between 1991 and 2013 among 
survivors according to time between cancer diagnosis and delivery, compared to siblings 
(unpublished results). 
 
Outcome1 Elapsed time from cancer treatment to delivery 
 Deliveries of 
siblings 
(N=16,787) 
n             OR 
(%)       (95%CI) 
Less than 6 years 
 
(N=1,307) 
n                       OR 




n                    OR 




n                   OR 

















































OR, odds ratio; CI, confidence interval 
1Adjusted for maternal age, year of delivery, parity and maternal smoking 
Statistically significant odds ratios are presented in bold font   
 
     
    Sub-analyses on fertility treatments leading to birth according to different cancer 
types, mostly resulted in such small numbers that reporting them was not sensible. 
Notable, however, was the increased use of fertility treatments in thyroid cancer 
survivors compared to siblings (OR 2.72, 95% CI 1.26-5.86), as 39 (5.4%) of all thyroid 
cancer survivors giving birth in 1991-2013 had undergone fertility treatments 






5.2 PREGNANCY-RELATED CONDITIONS (STUDY III) 
This study, placed focus on pregnancy-related conditions, exploring possible 
conditions that could explain the increased risk of preterm delivery previously 
observed in cancer survivors (Signorello et al. 2006, Madanat-Harjuoja et al. 2010, 
van der Kooi et al. 2018). In addition to the original results, it presents new 
unpublished data on placental pathologies, malpresentation, diseases of the 
circulatory system and use of LMWH medication in cancer survivors compared to 
comparison subjects. Preterm deliveries were more common among cancer survivors 
compared to comparison subjects, as 7.4% of cancer survivors and 5.2% of 
comparison subjects delivered preterm (less than 37 gestational weeks) (p=0.004). 
Regarding different time periods of delivery, the prevalence of preterm delivery was 
similar in 1991-2003 and 2004-2013. Table 13 shows that cancer survivors delivered 
at a higher age than the population comparisons (mean age 29.7 and 27.6 years, 
respectively, p<0.001) and more often during the most recent time period (2003-
2013, p<0.001). 
 
Pregnancy-related conditions were divided into those possibly resulting in 
spontaneous preterm delivery and those possibly leading to medically induced 
preterm delivery. We did not observe an increased risk (Table 14) for conditions 
possibly leading to spontaneous preterm delivery (threatened preterm labor and 
preterm rupture of the membrane). However, with regard to maternal pregnancy-
related conditions possibly leading to medically induced preterm delivery, cancer 
survivors had an increased risk for IHC, fear of childbirth, mental disorders and 
diseases of the nervous system, as well as use of LMWH medication (Table 14). The 
overall risk was not increased for pre-eclampsia, vaginal bleeding, placental 
pathologies, GDM, malpresentation or diseases of the circulatory system. However, 
we observed an increased risk for overall hospitalization. A separate analysis 
according to year of delivery revealed that the risk for overall hospitalization in 
cancer survivors compared to comparison subjects was lower during the most recent 
time period of 2003-2013 (OR 1.30, 95% CI 1.02-1.65) than 1991-2002 (OR 1.55, 95% 
CI 1.22-1.97). 
 
To study whether cancer survivors with a certain pregnancy related outcome had 
an excess risk of preterm delivery compared to corresponding comparison subjects 
and survivors without the pregnancy-related condition, we performed a separate 
analysis. We observed an increased risk for preterm delivery in survivors with vaginal 
bleeding (OR 1.35, 95% CI 1.07-247 1.71) and pre-eclampsia (1.35, 95% CI 1.06-1.72) 
compared to comparison subjects with the same condition. The original publication 




Table 13 Diagnostic characteristics of female cancer survivors and descriptive 








Characteristics Subcategory Survivors 
(N=1,753) N (%) 
Comparisons 
(N=5,123) N (%) 
P-value 
Year of diagnosis 1957-1972 12 (0.68) -  
 1973-1992 666 (37.99) -  
 1993-2012 1,075 (61.32) -  
Age at diagnosis 0-14 398 (22.70) -  
 15-24 770 (43.92) -  
 25-39 585 (33.37) -  
Time from diagnosis 








 6-10 474 (27.04) -  
 11-38 550 (31.37) -  
Cancer treatment Chemotherapy 556 (31.72) -  
 Radiotherapy 559 (31.89) -  
 Surgery, only 712 (40.62) -  
 Missing 219 (12.49) -  
     
Age at delivery <25 331 (18.88) 1,515 (29.57) <0.001 
 25-29 599 (34.17) 2,111 (41.21)  
 30-34 552 (31.49) 1,149 (22.43)  
 35 or more 271 (15.46) 348 (6.79)  










 2003-2013 1,088 (62.07) 2,538 (49.54)  
Maternal smoking No 1,494 (85.23) 4,130 (80.62) 0.056 
 Yes 227 (12.95) 885 (17.28)  
 Missing 32 (1.83) 108 (2.11)  
Gestational age <32 32 (1.83) 42 (0.82) 0.004 
 32-36 97 (5.53) 226 (4.41)  
 37-41 1,513 (86.31) 4,528 (88.39)  
 42 or more 109 (6.22) 316 (6.17)  
 Missing 2 (0.11) 11 (0.21)  
Birth weight (g) <1500 31 (1.77) 36 (0.70) 0.002 
 1500-2499 73 (4.16) 163 (3.18)  
 2500-3999 1,421 (81.06) 4,218 (82.33)  
 4000-4499 205 (11.69) 619 (12.08)  
 4500 or more 23 (1.31) 87 (1.70)  
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Table 14 Adjusted odds ratios (ORs) for pregnancy outcomes between 1991 and 2013 
among female cancer survivors with their first post diagnosis pregnancy compared with 
first pregnancies in a matched female group (unpublished results on placental pathologies, 
malpresentation, diseases of the circulatory system and use of LMWH medication) 
 






Any hospitalization 394 (22.48) 906 (17.68) 1.45 (1.25-1.68) 
Pregnancy outcomes possibly leading to spontaneous preterm delivery 
Hospitalization for threatened preterm labor 49 (2.80) 105 (2.05) 1.39 (0.91-2.12) 
Preterm rupture of the membranes2 41 (4.08) 68 (3.04) 1.21 (0.67-2.17) 
Pregnancy outcomes possibly leading to medically induced preterm delivery 
Hospitalization for pre-eclampsia 97 (5.53) 258 (5.04) 1.11 (0.85-1.45) 
Hospitalization for vaginal bleeding 24 (1.37) 52 (1.02) 1.31 (0.74-2.31) 
Placental pathologies 49 (2.80) 107 (2.09) 1.07 (0.73-1.57) 
Gestational diabetes2 109 (10.85) 196 (8.77) 1.06 (0.78-1.43) 
Intrahepatic cholestasis2 18 (1.79) 20 (0.89) 2.86 (1.09-7.49) 
Malpresentation 151 (8.61) 420 (8.20) 0.98 (0.80-1.21) 
Fear of childbirth2 42 (4.18) 46 (2.06) 2.25 (1.31-3.85) 
Mental disorders and diseases of the 
nervous system2 
28 (2.79) 16 (0.72) 5.89 (2.31-15.00) 
Diseases of the circulatory system2 4 (0.40) 4 (0.18) 3.65 (0.37-35.83) 
Use of  LMWH medication2 28 (2.79) 22 (0.98) 2.76 (1.26-6.03) 
 
OR, odds ratio; CI, confidence interval; LMWH, low molecular weight heparin 
1Adjusted for maternal age, gestational age and maternal smoking 
2Data available from 2004-2013 (1,005 survivors and 2,236 female controls) 
Statistically significant odds ratios are presented in bold font  
 
 
As many as 9.3% of childhood cancer survivors, 6.5% of survivors diagnosed as 
adolescents and 7.2% of survivors diagnosed as young adults delivered preterm. 
Regarding maternal pregnancy-related conditions, the risks were most elevated in 
adolescents. This group had the highest risk for overall hospitalization (OR 1.62, 95% 
CI 1.24-2.10), hospitalization for vaginal bleeding (OR 2.83, 95% CI 1.11-7.18) and fear 
of childbirth (OR 3.72 95% CI 1.15-12.02) compared to comparison subjects. 
 
Regarding preterm delivery according to elapsed time between cancer diagnosis 
and delivery, 6.9% of all survivors delivering within six years of cancer diagnosis had 
a preterm delivery, whereas the number for those delivering 6-11 years after cancer 
diagnosis was 6.3%; it was 8.9% for those delivering more than 11 years after cancer 
diagnosis. The risk for overall hospitalization was highest among those delivering less 
than six years from cancer diagnosis (OR 1.75, 95% CI 1.34-2.30), second highest 
among those delivering 6-10 years from cancer diagnosis (OR 1.43, 95% CI 1.01-2.03). 
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The risk for hospitalization did not increase in women delivering 11 years or more 
after cancer diagnosis (OR 1.08, 95% CI 0.75-1.54). 
 
Among cancer survivors treated with chemotherapy, 9.9% delivered preterm. The 
prevalence was 7.3% among survivors treated with radiotherapy. A separate analysis 
of those treated with abdominal radiotherapy (107 survivors) revealed that 7.8% 
delivered preterm. Of survivors treated with surgery, 6.5% were preterm deliveries. 
The risk for overall hospitalization showed an increase in all treatment-groups but 
was highest among survivors treated with surgery (OR 1.58, 95% CI 1.16-2.14). 
Cancer types with the highest number of preterm deliveries were renal tumors 
(30.0%), tumors of the sympathetic nervous system (16.7%), leukemia (13.9%) and 
malignant bone tumors (13.5%). The original publication (Study III) presents a 
descriptive supplemental table on pregnancy-related conditions according to cancer 
type.  
5.3 OBSTETRIC OUTCOMES (STUDY IV) 
Study IV focused on obstetric outcomes in cancer survivors compared to siblings.  
It also presents new unpublished data on prolonged labor, fetal asphyxia, emergency 
CS and anal sphincter injury in addition to the original results. In our data, cancer 
survivors were older compared to siblings (p<0.001). Cancer survivors also had more 
preterm deliveries and lower birth weight of the offspring and delivered more often 
in the most recent time periods compared to siblings (p<0.001). Survivors were less 
likely to smoke than their siblings (p<0.001). 
 
Table 15 shows that cancer survivors had an increased risk for induction of labor 
(OR 1.17 95% CI 1.02-1.35) and elective CS (OR 1.36 95%CI 1.11-1.67). However, the 
overall risk for urgent or emergency CS did not increase in cancer survivors. Common 
indications for urgent or emergency CS are prolonged labor or suspicion of fetal 
asphyxia, which was not increased in cancer survivors compared to siblings. Table 16 
presents different types of medical pain relief during vaginal delivery (unpublished 
results). We observed a crude, unadjusted increased risk for any medical pain relief 
as well as epidural and spinal anaesthesia in survivors compared to siblings. However, 
after adjusting for maternal age, year of delivery, gestational age and maternal 







Table 15 Adjusted odds ratios (ORs) for obstetric outcomes among cancer survivors giving 
birth compared to siblings (unpublished results on prolonged labor, fetal asphyxia, 
emergency CS and anal sphincter injury). 
 






Induction of labor 344 (19.1) 1,113 (15.6) 1.17 (1.02-1.35) 
Prolonged labor3 67 (8.44) 186 (8.88) 0.88 (0.65-1.19) 
Fetal asphyxia2 86 (5.28) 252 (4.35) 1.05 (0.81-1.35) 
Vaginal birth 1,120 (62.2) 4,960 (69.5) 0.87 (0.78-0.97) 
Instrumental vaginal birth 241 (13.4) 793 (11.1) 1.07 (0.91-1.25) 
Cesarean section 424 (23.6) 1,329 (18.6) 1.15 (1.01-1.31) 
Elective CS2 153 (9.4) 375 (6.5) 1.36 (1.11-1.67) 
Urgent CS2 243 (14.9) 750 (13.00) 1.04 (0.89-1.23) 
Emergency CS3 21 (2.64) 37 (1.77) 1.47 (0.85-2.54) 
Anal sphincter injury3 13 (1.64) 29 (1.38) 1.13 (0.58-2.20) 
Postpartum hemorrhage3 34 (4.3) 72 (3.4) 1.19 (0.78-1.81) 
OR, odds ratio; CI, confidence interval 
1Adjusted for maternal age, year of delivery, gestational age and maternal smoking 
2Data available from 1991-2013 (1630 survivors, 5790 siblings) 
3Data available from 2004-2013 (794 survivors, 2,094 siblings) 




Table 16 Crude and adjusted odds ratios (ORs) for medical pain relief among cancer 
survivors with vaginal delivery compared to siblings (unpublished results). 
 








Any medical pain relieve 1,129 (82.17) 4,499 (77.57) 1.33 (1.15-1.55) 0.89 (0.75-1.06) 
Epidural analgesia 739 (53.78) 2,803 (48.33) 1.24 (1.10-1.40) 0.92 (0.81-1.05) 
Spinal anaesthesia3 43 (7.20) 83 (4.99) 1.48 (1.01-2.16) 1.51 (1.03-2.22) 
Paracervical block 
anaesthesia 
229 (16.67) 1,028 (17.72) 0.93 (0.79-1.09) 1.02 (0.86-1.19) 
Pudendal nerve block 53 (3.86) 200 (3.45) 1.12 (0.83-1.53) 0.83 (0.60-1.13) 
Systemic nitrous oxide2 757 (61.44) 2,749 (59.00) 1.11 (0.97-1.26) 1.06 (0.93-1.21) 
Other medical pain 
relieve3 
112 (18.76) 328 (19.74) 0.94 (0.74-1.19) 0.98 (0.77-1.25) 
OR, odds ratio; CI, confidence interval 
1Adjusted for maternal age, year of delivery, gestational age and maternal smoking 
2Data available from 1991-2013 (1,232 survivors, 4,659 siblings) 
3Data available from 2004-2013 (597 survivors, 1,662 siblings) 




Sub-analyses according to age at cancer diagnosis revealed that cancer survivors 
treated in their childhood had the highest risks for adverse obstetric outcomes. They 
had the highest risk for induction of labor (OR 1.38, 95% CI 1.02-1.86) and overall CS 
(OR 1.48, 95% CI 1.11-1.96) and this was the only diagnostic age group with an 
increased risk for urgent CS (OR 1.40 95% CI 1.02-1.94). This group also had the 
lowest odds for normal vaginal delivery (OR 0.70, 95% CI 0.54-0.90). In contrast, we 
found no increased risks for those survivors diagnosed with cancer in adolescence or 
as young adults. 
 
Regarding cancer treatment, survivors treated with chemotherapy had the 
highest risk for adverse obstetric outcomes as the risk for induction of labor (OR 1.43, 
95% CI 1.09-1.87), overall CS (OR 1.42, 95% CI 1.10-1.83) and urgent CS (OR 1.37, 95% 
CI 1.08-1.75) were increased. Survivors treated with radiotherapy did not have an 
increased risk for any of the outcomes studied. A separate analysis of 96 survivors 
treated with abdominal radiotherapy revealed no increased risks compared to 
siblings, but the numbers were small. Studying obstetrics outcomes according to 
cancer type revealed that, survivors treated for CNS tumors had an increased risk for 
overall CS (OR 1.69, 95% CI 1.22-2.33) and elective CS (OR 2.14, 95% CI 1.34-3.42).  
 
Table 17 describes the adjusted ORs for different obstetric outcomes among 
cancer survivors and siblings who underwent CS. Survivors had a higher proportion 
of fear of childbirth, pre-eclampsia and inductions of labor than siblings. However, 
none of the outcomes were significantly increased in survivors compared to siblings. 
 
 
Table 17 Adjusted odds ratios (ORs) for obstetric outcomes during 1991 to 2013 among 
cancer survivors and siblings undergoing cesarean sections (unpublished results). 
 
Obstetric outcome Survivors with CS 
N=396 (%) 




Fear of childbirth2 19 (9.64) 28 (6.48) 1.60 (0.85-3.00 
Pre-eclampsia 38 (9.60) 98 (8.71) 1.06 (0.70-1.59) 
Gestational diabetes2 20 (10.15) 51 (11.81) 0.86 (0.49-1.52) 
Malpresentation 107 (27.02) 326 (28.98) 0.90 (0.69-1.17) 
Placental pathology 7 (1.77) 26 (2.31) 0.70 (0.30-1.66) 
Induction of labor 78 (19.70) 209 (18.58) 1.08 (0.79-1.47) 
Long labor2 24 (12.18) 77 (17.82) 0.71 (0.42-1.18) 
Fetal asphyxia 47 (11.87) 131 (11.64) 0.94 (0.65-1.34) 
 
CS, cesarean section; OR, odds ratio; CI, confidence interval 
1Adjusted for maternal age, year of delivery, gestational age and maternal smoking 
2Data available from 2004-2013 (794 survivors, 2,094 siblings)  
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5.3.1 BIRTH RATES (STUDY IV) 
 
     Study IV calculated the birth rates in cancer survivors, according to age at cancer 
diagnosis in different cancer types (Table 18). The entire cohort comprised 13,799 
cancer survivors diagnosed at the age of 0-34 years. Of 2,765 female childhood 
cancer survivors, 487 (17.6%) delivered at least one child later in life. Of 2,707 cancer 
survivors, diagnosed as adolescents, 886 (32.7%) delivered at least one child after 
cancer diagnosis. In our cohort, 8,327 survivors were diagnosed with cancer as young 
adults. Of these cancer survivors, 1,028 women (12.3%) delivered after their cancer 
diagnosis at the end of our follow up in December 2013.  
 
Table 18 Numbers and percentages of female cancer survivors with deliveries at least 9 
months after cancer diagnosis, by primary site of cancer and age at cancer diagnosis.  
 
                                          Cancer survivors with deliveries               All female cancer survivors 
    Age at diagnosis                   0-14                 15-24               25-34              0-14       15-24      25-34      
Primary site                         n (%)                    n  
Leukemia 161 (18.6) 32 (14.5) 9 (3.4) 868 220 263 
Lymphoma 46 (21) 212 (39.1) 129 (17.3) 219 542 744 
CNS 83 (12.0) 81 (23.5) 70 (9.1) 690 344 771 
Symp Nervous Syst 19 (11.4) 3 (17.6) 5 (29.4) 166 17 17 
Retinoblastoma 13 (16.0) 0 0 81 0 0 
Renal Tumors 36 (20.9) 7 (36.8) 10 (11.2) 172 19 89 
Hepatic Tumors 0 0 1 (2.2) 18 15 46 
Malignant bone 18 (18.2) 27 (22.1) 7 (6.8) 99 122 103 
Soft tissue and other 
Sarcomas 
39 (22.5) 75 (29.6) 67 (13.9) 173 253 481 
Germ Cell, Gonadal, 
Trophobl 
10 (12.2) 52 (23.0) 42 (7.7) 82 226 546 
Carcinomas and other 
malign. epith. neopl. 
60 (35.9) 389 (42.8) 679 (13.2) 167 908 5160 
           Thyroid 11 (28.2) 160 (46.0) 242 (24.2) 39 348 999 
           Cervix 0 3 (10.7) 32 (4.7) 0 28 679 
           Uterus 0 0 1 (1.4) 0 2 71 
           Breast 1 (100) 8 (21.1) 110 (6.6) 1 38 1,665 
           Stomach 0 1 (10.0) 6 (3.4) 0 10 177 
          Colon 28 (45.9) 78 (47.9) 50 (15.9) 61 163 315 
          Melanoma 7 (36.8) 98 (51.6) 169 (23.3) 19 190 724 
          Other Carcinomas 13 (27.7) 36 (27.9) 67 (12.6) 47 129 530 
Others 2 (6.7) 8 (19.5) 9 (8.4) 30 41 107 




6.1 FERTILITY TREATMENTS 
Parenthood is less probable among cancer survivors (Madanat et al. 2008) and 
they also have lower pregnancy rates compared to the general population 
(Stensheim et al. 2011, Anderson et al. 2018). With regard to infertility and fertility 
treatments in cancer survivors, only a few studies exist in the literature, most of them 
with a follow up that ends in an earlier time period than ours (Barton et al. 2013 and 
Haggar et al. 2014, Luke et al 2016).  
 
Study I found that cancer survivors had an increased use of fertility drugs 
compared to female sibling. This is in discordance with the American Childhood 
Cancer Survivor Study (Barton et al. 2013), in which cancer survivors were less likely 
(RR 0.57) to be prescribed fertility drugs compared to their siblings, although they 
had an increased risk (RR 1.48) of clinical infertility (defined as more than one year 
of unsuccessful attempts at conception) and were as likely as their siblings to seek 
medical help for their condition.  
 
A sub-classification of fertility treatments into OI and ART showed that the overall 
increased use of fertility drugs could be explained by the increased use of ART, which 
was 2.4-fold in cancer survivors compared to siblings. The use of OI was similar in 
cancer survivors and siblings. OI is usually considered the first line treatment in 
ovulation disorders and unexplained infertility, as it is non-invasive, less expensive 
and easier to perform than ART. OI was more common than ART in siblings in our 
data. However, among cancer survivors, ART was more common, probably because 
of higher success rates, especially when the ovarian reserve is reduced. It is well 
known that cancer treatments, especially abdominal radiotherpay and 
chemotherapy with alkylating agents, may damage the ovaries, leading to a 
narrowed fertile time window in cancer survivors (Wallace et al. 1989, Anderson et 
al. 2013, Freour et al. 2017).  This probably explained the increased use of more 
advanced fertility treatments (ART) at the cost of easier, less invasive fertility 
treatments (OI) in cancer survivors. 
 
Time period played a central role in use of overall fertility treatments and ART, 
increasing from 2003 onwards in survivors compared to siblings (Study I). Comparing 
our results to the American childhood cancer survivor study (Barton et al. 2013), it is 
noteworthy that the results in their study are from an earlier time period, between 
1992 and 2004, compared to ours. After this several studies (Meirow et al. 2014, 
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Oktay et al. 2015 and Goldrat et al. 2015) stated that, although limited data are 
available, fertility treatments do not seem to increase the risk for cancer recurrence. 
According to one study on breast cancer patients undergoing ART compared to 
breast cancer patients without fertility treatments, no differences were found in 
overall survival rates and relapse of cancer (Goldrat et al. 2015).  In the light of these 
findings, it is possible that the use of fertility treatments has also increased in 
American cancer survivors during recent years.  
 
Study II analyzed the association of being a cancer survivor giving birth and using 
fertility treatments. The use of overall fertility treatments in cancer survivors giving 
birth from 1991-2013 was increased in survivors compared to siblings. An even 
higher use of fertility treatments was observed among survivors giving birth from 
2004-2013. However, a sub-classification of overall fertility treatments into OI, IUI 
and ART revealed no increased risks in cancer survivors compared to siblings.  We 
found one study (Haggar et al. 2014) similar to ours that analyzed the risk of fertility 
treatments in cancer survivors giving birth. They found an increased use of fertility 
treatments in cancer survivors compared to a control group without cancer (RR 1.94). 
However, that study did not take into account different cancer treatments, age at 
cancer diagnosis or elapsed time between cancer treatment and delivery. Survivors 
included in that study were 15-39 years of age at cancer diagnosis, and the follow up 
ended in 2007.  
 
Our two studies on fertility treatments in cancer survivors and their siblings, 
showed similar results. Differences in the two studies included the study design 
(Study I calculated IRR and Study II ORs) and cohort size of the cancer survivors which 
was more than two-fold in Study I compared to Study II. Study I analyzed the use of 
fertility treatments between 1993 and 2012 and included only women without 
biological children. Study II analyzed fertility treatments between 1991 and 2013 and 
included subsequent pregnancies of the same mother.  
 
6.2 PREGNANCY-RELATED CONDITIONS 
Study III assessed pregnancy-related outcomes in cancer survivors and age-
matched female comparisons. Our aim was to identify the underlying reasons for the 
increased risk of preterm deliveries in cancer survivors, observed in several previous 
studies (Madanat-Harjuoja et al. 2010, Anderson et al. 2017 and van der Kooi et al. 
2018). This was done by dividing pregnancy-related conditions in cancer survivors 
and comparison subjects into those leading to spontaneous preterm delivery and 




Studies have shown that especially abdominal irradiation and chemotherapy with 
busulfan can damage the uterus (Larsen et al. 2004, Beneventi et al. 2015), resulting 
in fibrosis and reduced blood flow. This, in turn, could lead to premature contractions 
and rupture of the amniotic membranes, possibly resulting in spontaneous preterm 
delivery. In our study, being a cancer survivor was not associated with an increased 
risk for conditions leading to spontaneous preterm delivery (premature rupture of 
the amniotic membranes or hospitalization for threatened preterm labor) compared 
to matched comparison subjects. Cancer survivors with hospitalization for 
threatened preterm labor or premature rupture of amniotic membranes did not have 
a higher risk than that of corresponding comparison subjects for preterm delivery 
either. Only a few studies (Green et al. 2010, Haggar et al. 2014, Reulen et al. 2017) 
exist that investigated pregnancy-related outcomes possibly leading to spontaneous 
preterm delivery and similar to our study, they found no increased risk in cancer 
survivors compared to siblings or healthy female controls. One explanation for the 
similar risk of spontaneous preterm delivery in survivors and comparison subjects 
could be that cancer survivors with a severely damaged uterus due to toxic cancer 
treatments could not achieve pregnancy in the first place. A Danish study (Winther 
et al. 2008) found cancer survivors treated with abdominal radiotherapy to have an 
increased risk for spontaneous abortion, possibly indicating that radiation-induced 
damage in the uterus might complicate the implantation of the embryo and lead to 
early pregnancy loss. 
 
Concerning pregnancy-related conditions possibly leading to medically induced 
preterm delivery, being a cancer survivor was associated with an increased risk for 
fear of childbirth, IHC, mental disorders and diseases of the nervous system, use of 
LMWH medication and overall hospitalization during pregnancy compared to 
comparison subjects. When comparing our results to other studies on pregnancy 
outcomes possibly leading to medically induced preterm delivery, we found that the 
results were conflicting. Previous studies (Green et al. 2010, Haggar et al. 2014, 
Reulen et al. 2017) found an increased risk for pre-eclampsia and GDM in cancer 
survivors, especially among those treated with abdominal irradiation, whereas we 
observed no overall increased risk for these outcomes. Regarding pre-eclampsia, it is 
notable that our study measured cases of pre-eclampsia requiring hospitalization, 
leaving out the less severe pre-eclampsia cases, possibly affecting the result. In 
additional analyses of the reasons behind the preterm deliveries in cancer survivors, 
we observed that both vaginal bleeding and pre-eclampsia in cancer survivors were 
associated with an increased risk for preterm delivery compared to corresponding 
comparison subjects. Our findings may indicate that these conditions are more 
severe among cancer survivors, as they more often lead to preterm delivery in 
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survivors compared to comparison subjects with the same condition. However, the 
policy to induce labor or perform CS varies among physicians, and awareness of a 
previous cancer may have affected their decision to terminate the pregnancy. This 
could also explain the higher risk of hospitalization among cancer survivors during 
pregnancy.  
 
We have found no previous reports on fear of childbirth, mental disorders and 
diseases of the nervous system, IHC or use of LMWH medication during pregnancy in 
cancer survivors. According to two studies (Saisto et al. 1999, Melender et al. 2002), 
6-10% of pregnant women in the Nordic countries suffer from fear of childbirth. Fear 
of childbirth is often the underlying reason for a mothers request for CS (Nieminen 
et al. 2017). It also goes hand in hand with mental disorders, as women with fear of 
childbirth are twice as likely to suffer from mental health problems compared to 
women without fear of childbirth (Rouhe et al. 2011). The most common mental 
disease in pregnant women is depression with a prevalence of 10-15% among all 
pregnant women (Gavin et al. 2005).  In an American study, cancer survivors reported 
medication use for anxiety and depression at rates nearly two times those reported 
by the general population (Hawkins et al. 2017). Other studies have reported an 
increased risk for psychological distress and psychosocial problems, especially in 
survivors diagnosed as AYAs (Mody et al. 2008, Krull et al. 2010). If left unaddressed 
and untreated, anxiety and depression in cancer survivors have been found to affect 
negatively on health behavior (Stark et al. 2002), which could lead to mental 
disorders and fear of childbirth emerging during pregnancy. 
 
    One Scandinavian study (Asdahl et al. 2016) on childhood cancer survivors showed 
that cancer survivors have an overall increased risk for liver diseases (RR 1.60). In the 
light of these findings, it is not surprising that being a cancer survivor was associated 
with an increased risk for IHC compared to comparison subjects in our study. Being a 
cancer survivor was also associated with an increased use of LMWH medication 
during pregnancy compared to comparison subjects. This is a new, but not surprising, 
finding. According to one study by Bajzar et al., childhood cancer patients have a 
prevalence of 7-14% for symptomatic DVT and a more than 40% prevalence of an 
asymptomatic DVT (Bajzar et al 2006). Concerning cancer treatments, chemotherapy 
was most often associated with a DVT in childhood cancer patients (Mitchell et al. 
2010). Antithrombotic therapy with LMWH is recommended for pregnant women 
with a history of DVT (Bates et al. 2018), presumably explaining the increased use of 
LMWH medication among cancer survivors in our study. Scheduled delivery with 
prior discontinuation of LMWH is suggested (Bates et al. 2018), potentially increasing 
the risk for induction of labor in these women. In addition, women with 
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hospitalization due to threatened preterm labor are often treated with LMWH (Duhl 
et al. 2007).  
In order to identify cancer survivors with cardiac diseases, due to cardiotoxic 
cancer treatments, we studied the risk for diseases of the circulatory system 
complicating pregnancy, childbirth or puerperium (ICD-10 code O99.4) in cancer 
survivors. Being a cancer survivor was not associated with an increased risk for 
diseases in the circulatory system during pregnancy compared to comparison 
subjects in our data, but the numbers were small (4 survivors and 4 comparison 
controls). In a previous study (Hines et al. 2016), the prevalence for pregnancy-
associated cardiomyopathy in cancer survivors was 0.3%; surveillance for 
cardiomyopathy before pregnancy or during the first trimester of pregnancy is 
recommended in survivors treated with anthracyclins or chest irradiation (Armenian 
et al. 2015).  
 
Our study found that the proportion of preterm deliveries in cancer survivors 
during the time period of 1991-2002 and 2003-2013 was similar (7.4%). The total rate 
of preterm deliveries in Finnish women is low compared to the rest of Europe 
(Räisänen et al. 2013) and has remained stable during the current decade, being 5.3% 
in 2017 (Statistics Finland 2018). 
6.3 OBSTETRIC OUTCOMES 
When we conducted our study on obstetric outcomes in cancer survivors and 
their siblings, only a few previous studies (Clark et al. 2007, Muller et al. 2009, Haggar 
et al. 2014) were available on these outcomes. Similar to ours, they found an overall 
increased risk for CS in cancer survivors. Our study subclassified overall CS into 
elective, urgent and emergency CS. Only the risk for elective CS was increased. This 
was a new finding then, which has later been verified in two other studies (Reulen et 
al. 2017, van der Kooi 2018), that found an increased risk (RR 1.39 and 1.59, 
respectively) for cancer survivors to opt for elective CS compared to the general 
population.  
 
It is reassuring that the increased risk for overall CS is explained by elective CS 
(where the decision to operate is made before onset of delivery), as urgent and 
emergency CS are associated with higher risks for complications (Krebs et al. 2003, 
Pallasmaa et al. 2010). According to a Finnish study (Pallasmaa et al. 2010), there was 
a two-fold increased risk for intraoperative complications and infections in urgent CS 
compared to elective CS. Our further analyses comparing cancer survivors with CS to 
siblings with CS revealed no significant differences in cancer survivors and siblings. 
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However, we observed higher rates of fear of childbirth, pre-eclampsia and induction 
of labor in cancer survivors delivering by CS compared to corresponding siblings. 
 
Being a cancer survivor was associated with an increased risk for induction of 
labor when compared to siblings. We found only one previous study on induction of 
labor (Clark et al. 2007), which reported no increased risk. In that study the follow up 
ended in 2004, and the difference in CS rates in cancer survivors and controls was 
quite big (27.3% and 17.2%, respectively), whereas the difference in induction rates 
was quite small (29.6% and 27.8%, respectively). It is possible that the pregnancies 
in these cancer survivors were rather terminated by CS than induction of labor.The 
rates of induction of labor are increasing worldwide, being 20-30% in the Western 
world (Zeitlin et al. 2013). In 2013, 20.5% of all deliveries in Finland were induced 
compared to 28.9% in 2017 (Statistics Finland 2018). One Finnish study found that 
induction of labor was associated with an increased risk for CS by up to 37% (Kruit et 
al. 2015). However, there are conflicting results, and two other studies (Rattigan et 
al. 2013 and Little et al. 2017) found that elective induction of labor did not increase 
the risk for CS and even reduced the risk for neonatal morbidity and possible stillbirth 
(Little et al. 2017). Our study found that the increased risk for induction of labor did 
not explain the increased risk for CS in cancer survivors. 
 
The association between being a cancer survivor and the increased risk for 
induction of labor and elective CS may be partially explained by the increased OR for 
fear of childbirth, mental disorders and diseases of the nervous system, IHC and use 
of LMWH medication during pregnancy. These are all conditions known to increase 
the risk for induction of labor and CS (Nieminen et al. 2017, Tanne et al. 2008, Geenes 
et al. 2014 and Bates et al. 2018). However, it has previously been hypothesized that 
a history of cancer could lead to increased surveillance and a lower threshold for 
interventions (Thomson et al. 2005 and Clark et al. 2007), which could also explain 
the increased risk for induction of labor and CS among cancer survivors. 
 
One recent study by Sitras et al. showed that pregnant women with fear of 
childbirth and mental health problems had increased odds for choosing epidural 
analgesia compared to women without these conditions (Sitras et al. 2017). Cancer 
survivors are at risk for pain syndromes and also have an increased risk for fear of 
childbirth and mental disorder and diseases of the nervous system, so our hypothesis 
was that they might also have an increased use of medical pain relief during delivery 
compared to siblings. Pain is a common problem in cancer survivors, and according 
to a recent study (Karlson et al. 2018), 29% of adult childhood cancer survivors 
(median age 31 years) reported moderate to severe pain. Survivors with chronic 
health conditions, depression and anxiety were most likely to report chronic pain 
 Discussion 
79 
(Karlson et al. 2018). The pain mechanism varies with cancer treatment. Surgery is 
known to potentially cause persistent postsurgical syndromes such as 
postmastectomy pain and phanthom limb pain (Glare et al. 2014), whereas 
radiotherapy can cause plexopathies and osteoradionecrosis (Dropho et al. 2010). 
The most common pain syndrome is generally thought to be chemotherapy-induced 
peripheral neuropathy, which is associated with specific chemotherapeutic agents 
(Glare et al. 2014). Our study found that 53.8% of the cancer survivors and 48.3% of 
their siblings received epidural analgesia during vaginal delivery. For any medical pain 
relief, epidural analgesia and spinal anaesthesia, the crude OR was increased but 
after adjusting for maternal age, year of delivery, gestational age and maternal 
smoking, only the risk for spinal anaesthesia was increased. It is notable, that data 
on spinal anaesthesia is only available from 2004 onwards, whereas data on epidural 
analgesia is available from 1987 onwards. A larger proportion of cancer survivors 
delivered after 2004 compared to siblings (43.4% and 28.7%, respectively), which 
might have affected the results. To our knowledge, use of medical pain relief in 
cancer survivors have not been studied before. 
6.4 THE ASSOCIATIONS OF CANCER CHARACTERISTICS AND 
VARIOUS REPRODUCTIVE VARIABLES 
6.4.1 AGE AT CANCER DIAGNOSIS 
 
Cancer patients treated in their childhood had the lowest use of fertility 
treatments, whereas the overall use of fertility treatments and more extensive 
fertility treatments (ART) was highest among cancer survivors diagnosed as young 
adults (Study II). These results suggest that prepubertal cancer treatments might be 
less harmful to the ovaries than cancer treatments received postpubertally. Age at 
cancer treatment has been found to be an important determinant for POI in previous 
studies of cancer survivors (Petrek et al 2006, Letourmeau et al. 2012). The higher 
the age of the girl/woman when receiving cancer treatment, the smaller the follicle 
pool in the ovaries; therefore, a smaller dose of radiation or chemotherapy is needed 
to cause POI in women at a higher age compared to younger women (Wallace et al. 
2005, Anderson et al. 2015). 
 
As for maternal pregnancy-related conditions according to age at cancer 
diagnosis, the strongest association was observed in adolescents, for whom we 
observed an increased OR for overall hospitalization, hospitalization for vaginal 
bleeding and fear of childbirth compared to comparison subjects. However, the 
highest incidence of preterm delivery was observed in childhood cancer survivors 
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(Study III). We found no other studies measuring the same pregnancy-related 
outcomes as we did according to age at cancer diagnosis. Concerning the risk for 
preterm delivery according to age at cancer diagnosis, we found two other studies 
(Haggar et al. 2014 and Anderson et al. 2017) measuring the risk. Haggar et al.´ study 
(2014) found that the risk for preterm delivery increased with a higher age at cancer 
diagnosis. Anderson et al.´s study (2017) found that the risk was quite similar in all 
age groups. These studies, however, only included women diagnosed with cancer at 
the age of 15-39 years of age, leaving out childhood cancer survivors, for whom the 
incidence for preterm delivery was highest in our study. 
 
Concerning adverse obstetric outcomes, childhood cancer survivors had the 
strongest association for these outcomes, as the OR for both induction of labor and 
CS was most increased in this diagnostic age group compared to siblings. Childhood 
cancer survivors were also the only diagnostic age group in which the OR for urgent 
CS was increased (Study IV). We found one study (van der Kooi et al. 2018) that 
compared delivery outcomes in the same diagnostic age groups as we did. In that 
study, childhood cancer survivors had the highest risk for elective CS (RR 3.15) and 
the lowest possibility for spontaneous vaginal delivery (RR 0.63). Similar to our study, 
the possibility for vaginal delivery increased with higher diagnostic age in cancer 
survivors. The higher risks for induction of labor and CS particularly in childhood 
cancer survivors are difficult to explain. It is possible that prepubertal cancer 
treaments on an undeveloped uterus are more harmful compared to postpubertal 
cancer treatments. Another explanation could be that CNS tumors, one of the most 
common childhood cancers, were associated with an increased risk for induction of 
labor and CS. 
6.4.2 TIME BETWEEN CANCER DIAGNOSIS AND DELIVERY 
 
Elapsed time between cancer diagnosis and delivery played a central role in the 
use of fertility treatments in cancer survivors giving birth. The use of fertility 
treatments increased over time, suggesting that cancer treatments lead to 
diminished ovarian reserve and a narrowed fertile time window in cancer survivors 
(Study II). This finding has been verified in a recent study (Levine et al 2018), where 
cancer survivors had a more than 10-fold increased risk for non-surgical premature 
menopause compared to siblings. Survivors with premature menopause had 
decreased pregnancy rates (RR 0.49) compared to survivors without premature 
menopause. Another study that supports our findings explored the use of ART in 
cancer survivors compared to healthy women (Luke et al. 2016) and found that the 
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live birth rate was reduced when autologous oocytes were used but that it was 
similar to healthy women when donor oocytes were used. 
 
Regarding pregnancy-related conditions and adverse obstetric outcomes in 
cancer survivors, we could not identify any trends according to the time between 
cancer diagnosis and delivery except for overall hospitalization, for which the 
association was highest among cancer survivors receiving a cancer diagnosis 0-5 
years before delivery (Study III and IV). No other studies measuring these pregnancy-
related conditions according to elapsed time between cancer diagnosis and delivery, 
were found. Anderson et al.´s study (2017) measured the risk for adverse obstetric 
outcomes (preterm delivery and CS, among other outcomes) and identified no trends 
according to time between cancer diagnosis and delivery. 
6.4.3 CANCER TYPE 
 
Being a survivor of thyroid cancer was associated with an increased use of overall 
fertility treatments (Study II). This was an unexpected finding, as previous studies 
found that radioactive iodine treatment of thyroid cancer did not decrease 
pregnancy rates compared to controls (Stensheim et al. 2011) and only seemed to 
cause temporary amenorrhea (Sawka et al. 2008). However, according to a recent 
study (Yaisha et al. 2018) premenopausal women with differentiated thyroid cancer 
treated with radioactive iodine treatment had an increased risk for POI. The POI 
diagnosis was based on measurements of AMH levels in serum, which were 32% 
lower than prior to treatment even one year after radioactive iodine use. The oocytes 
in the ovaries are believed to be at risk for injury while exposed to ionizing radiation 
excreted through the urine (Yaisha et al. 2018). 
 
Studying obstetrics outcomes according to cancer type, we found that being a 
survivor of CNS tumor was associated with an increased risk for CS (Study IV). This is 
in contrast to two other studies (Haggar et al. 2014, Reulen et al. 2017) in which they 
found an increased risk for CS in cancer survivors who suffered from leukemia, bone 
sarcoma or Wilms tumor but not CNS tumors. It is notable, however, that our 
analyses on pregnancy-related conditions and obstetric outcomes according to 






6.4.4 CANCER TREATMENT 
 
Our analyses that were stratified by cancer treatment, found no increased use of 
fertility treatments in the different treatment groups, with the exception of 
radioactive iodine treatment in thyroid cancer survivors, which was associated with 
an increased use of fertility treatments (Study II). Previous studies, however, found 
that radiation fields that include the ovaries and chemotherapy with alkylating 
agents cause the most extensive damage to the ovaries (Morgan et al. 2012, 
Anderson et al. 2015). Turcotte et al.´s study (2017) found that the use of alkylating 
agents has increased during recent years; it is possible that this could partly explain 
the increased use of fertility drugs in survivors. We found no association in our data 
between chemotherapy and an increased use of fertility treatments. It is impossible, 
however, to study outcomes by different chemotherapeutic agents or radiation 
doses from the FCR as this information is not available. We could roughly identify 
those who received abdominal radiotherapy by combining information on radiation 
and cancer site. 
 
 Radiotherapy is believed to damage the ovaries by a direct loss of follicles and 
oocytes in a dose-dependent manner (Anderson et al. 2015). The mechanism by 
which chemotherapy damages the ovaries is less clear, but alkylating agents are also 
believed to directly damage the follicles and the oocytes (Morgan et al. 2013). 
 
Regarding pregnancy-related conditions, survivors in all treatments groups had an 
increased risk for overall hospitalization compared to comparison subjects. However, 
the risk was highest among survivors treated with surgery. Cancer survivors treated 
with chemotherapy had the highest amount of preterm deliveries (Study III). Similar 
results were found in Anderson et al.´s study (2017), whereas cancer survivors 
treated with radiotherapy had the highest risk for preterm delivery in Haggar et al.´s 
study (2014). 
 
Concerning obstetric outcomes according to different cancer treatments, those 
treated with chemotherapy had the highest OR for induction of labor and overall CS. 
This group also had an increased OR for urgent CS. Similar results were observed in 
three other studies (Haggar et al. 2014, Anderson et al. 2017, Reulen et al. 2017) in 




6.5 SUMMARY AND CLINICAL IMPLICATIONS 
Our two studies on fertility treatments support previous findings (Barton et al. 2013) 
that cancer survivors have an increased risk for subfertility. During the most recent 
time period, from 2003 onwards the use of fertility treatments increased and were 
higher in cancer survivors compared to siblings. Elapsed time from cancer treatment 
and age at cancer diagnosis played a central role, and we found increased use of 
fertility treatments among women diagnosed with cancer as young adults and 
women receiving their cancer treatment a long time ago. A subclassification of 
fertility treatments into ART and OI revealed that the use of ART was higher in cancer 
survivors compared to siblings, whereas the use of OI was similar in both groups.  
 
Studying fertility treatments in cancer survivors is of clinical importance, since the 
need for fertility treatments largely reflects the damage to the ovaries caused by 
cancer treatments. Use of fertility treatments in cancer survivors also mirrors the 
attitude and knowledge of the treating physicians and the cancer survivors 
themselves. Our results indicate a more active approach among clinicians towards 
fertility treatments in cancer survivors during the most recent years. 
 
Thus, collaboration between oncologists and gynecologists is important in order 
to identify those at risk for infertility already when planning the cancer therapy, as 
well as for detecting ovarian dysfunction and POI later on. According to recent clinical 
guidelines (Oktay et al. 2018), the treating physician should discuss the possibility of 
infertility with all cancer patients or their parents/guardians as early as possible. 
Cancer survivors at risk of infertility should be provided options for fertility 
preservation. Oocyte and embryo preservations are standard methods that should 
be offered (Oktay et al. 2018). The field of ovarian tissue cryopreservation is 
advancing rapidly and will probably become a standard procedure in the future 
(Oktay et al. 2018). Alarmingly, according to a Swedish study (Armuand et al. 2012), 
only 48% of adult female cancer survivors reported that they received information of 
a possible reducement of their fertility due to cancer treatment. In contrast, males 
in the same study received information about the potential negative impact on 
fertility in 80% of the cases (Armuand et al. 2012). Another study found that infertility 
often came as a surprise for cancer survivors and that they had a false belief about 
their fertility (Oosterhuis et al. 2008).  
 
Fertility preservation for prepubertal girls with cancer in Finland is considered if 
the risk for infertility is very high, whereas for postpubertal girls and adult women it 
is considered if the risk for infertility is high (Finnish National recommendations for 
fertility preservation 2019, Table 2). After the cancer treatments, childhood and 
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adolescent cancer survivors attend follow ups at the pediatric clinic until the age of 
18 years. After that, the follow up for survivors with a high risk for late effects 
continues at late-effect clinics, established at all Finnish university hospitals. In some 
areas, survivors who are estimated to have a low risk for late effects can contact the 
late-effect clinic if needed, whereas the primary health care provider is responsible 
for the follow up in other areas. National Finnish guidelines recommend that all 
female childhood cancer survivors should be referred to a gynecologist after puberty 
onset (which is hormonally induced if spontaneous onset of puberty does not occur) 
to evaluate fertility and possible need for contraception. Ovarian reserve is evaluated 
by vaginal ultra-sound, estimating the AFC and by measuring the serum levels of 
AMH. Individual follow up based on the results is recommended. 
 
Study III showed that the increased risk for preterm delivery in cancer survivors 
was at least partially due to maternal pregnancy-related conditions (vaginal bleeding 
and pre-eclampsia) which might be more severe in cancer survivors compared to 
controls, possibly leading to medically induced preterm delivery. However, we could 
not rule out the possibility that the history of cancer influenced the health-care 
provider or the pregnant woman, eventually leading to increased surveillance and a 
lower threshold for medical intervention (Thomson et al. 2005, Clark et al. 2007). This 
goes hand in hand with cancer survivors having an increased risk for hospitalization 
during pregnancy. Early onset cancer survivors have been found to have an increased 
risk (RR 1.87) for overall hospitalization in adult life compared to matched controls, 
probably due to late morbidities after cancer treatment (de Fine Licht et al. 2017). 
Regarding obstetric outcomes (Study IV), cancer survivors had small but significantly 
increased odds for induction of labor and elective CS. All in all, the possibility for a 
spontaneous vaginal delivery was reduced compared to siblings. Being a childhood 
cancer survivor, as well as being treated with chemotherapy was associated with the 
highest risks for adverse obstetric outcomes.  
 
Health-care providers need to be aware of the increased risk for these pregnancy-
related conditions and adverse obstetric outcomes and consider individualized 
follow up. Our results were generally reassuring, however, and most cancer survivors 















Figure 9 An overview of the associations of cancer characteristics and increased odds for 
different outcomes in our studies 
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6.6 STRENGTHS AND LIMITATIONS 
      The studies in this thesis were based on data from high quality Finnish health 
registers. Our registers enabled long-term follow up covering a large number of 
women. The coverage and completeness of these registers are exceptionally high 
(Teperi et al. 1993, Gissler et al. 2002, Leinonen et al. 2017), making it possible to 
follow practically all individuals, without recall or reporting bias. Previous studies on 
late effects in cancer survivors are often based on self-reported questionnaires and 
medical records (Robison et al. 2009, Leisenring et al. 2009). A limitation in those 
kind of studies is recall bias. 
 
     A challenge when studying late effects of early onset cancer survivors is that the 
cancer treatment protocols change rapidly, and new treatments are frequently 
introduced (Stark et al 2015). Many studies of late effects in cancer survivors date 
back to an era of treatments that are no longer in use (Hawkins et al. 2008). 
Regarding the reproductive outcomes studied in this thesis, the follow ups ended in 
December 2012 (Study I) and December 2013 (Study II, III and IV). Most studies on 
reproductive outcomes in cancer survivors reviewed in this thesis, with the exception 
of three (Anderson et al. 2017, Anderson et al. 2018, van der Kooi 2018), have follow 
ups ending before ours.  
 
    The FCR has a high coverage, 96% for solid tumors and 86% for hematologic 
malignancies (Leinonen et al. 2017). A limitation, however, is the incomplete data on 
cancer treatments, making it impossible to study outcomes by different 
chemotherapeutic agents or radiation doses. We could roughly identify cancer 
survivors who had received abdominal radiation by combining information on 
radiotherapy and the cancer site 
 
    The MBR made it possible for us to study a large number of different outcomes 
and provided information on important confounders, making it possible to adjust for 
factors that might affect the outcomes studied. We would have liked to adjust for 
the women´s socioeconomic status but that information was missing for more than 
30% of the women. Information was probably lacking, because young women were 
studying or were at home with children. Instead, we adjusted for smoking, which is 
considered a good proxy for socioeconomic status (Jaakkola et al. 2001). As maternal 
obesity is increasing in women in the western world (Hansson et al. 2016) and has 
been found to affect many obstetric outcomes, it would have been important to 
adjust our analyses for obesity as well. However, as information on BMI was only 
available from 2004 onwards and missing in 6.6% of the cases, we decided not to 




Study I used information on prescribed fertility drug purchases from the RPM as 
a proxy for fertility treatments in cancer survivors. Only a few previous studies have 
investigated the use of fertility treatments in cancer survivors in a population-based 
registry setting. Study I is to our knowledge the first to use a nationwide drug 
prescription register to explore use of fertility drugs in cancer survivors. Drugs or drug 
combinations, classified as fertility drugs in this study, are rarely used for other 
indications. Cancer survivors with a registration of aromatase inhibitor use as a 
cancer treatment in the RPM (frequently used in breast cancer patients), were 
excluded from the follow-up. By using siblings as a comparison cohort, we could 
adjust for familial factors that could affect the use of fertility treatments. The main 
limitation in this study was that information was missing on whether the fertility drug 
was used for fertility preservation or as fertility treatment. Furthermore, RPM does 
not provide information on whether autologous or donor oocytes were used in ART. 
In addition, women diagnosed with cancer in the most recent time period had a short 
follow up, which might affect the result. Pregnancy and live birth rates after fertility 
treatments were not included in this study. 
 
Study II identified fertility treatments among cancer survivors and siblings giving 
birth. The main limitation in this study was that unsuccessful fertility treatments 
were not included. In the light of recent findings on clinical infertility and POI in 
cancer survivors (Barton et al. 2013, Anderson et al. 2015, Levine et al. 2018), we 
suspect that there were many cancer survivors with unsuccessful fertility treatments. 
A previous study showed that all fertility treatments are not documented in the MBR 
(Gissler et al. 2004). The information on fertility treatments is mostly received by self-
report of the mother, and many women might consider this sensitive information 
that they do not want to reveal. We suspect that there is an underestimation of 
fertility treatments in the MBR. As this possible underestimation applies to both 
cancer survivors and their siblings, we consider our results valid. 
 
The main strengths of Studies III and IV, were that we were able to produce novel 
information on several pregnancy-related conditions and obstetric outcomes that 
were never or rarely studied in cancer survivors before (IHC, fear of childbirth, mental 
disorders, placental pathologies, induction of labor, different subtypes of CS, to name 
a few). However, some of the outcomes studied were so rare (especially for sub-
analyses stratifying by cancer type) that we could not draw conclusions concerning 
the odds in cancer survivors compared to comparison subjects/siblings. ICD-10 
diagnoses are registered in the MBR from 2004 onwards. The registration of these 
ICD-10 diagnoses rely on the treating physician reporting them in the patients´ 
medical records. A patient with a less severe condition not requiring follow up at the 
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maternity clinic might not have an ICD-10 diagnosis in the MBR. For example, 10.8% 
of all cancer survivors in Study III were registered as having a pathological 2-h oral 
glucose tolerance test, the definition of GDM. However, only 8.7% of the cancer 
survivors ended up with an ICD-10 diagnostic code for GDM (O24.4 or O24.9) in the 
MBR. As this limitation concerned both cancer survivors and comparison subjects 
and siblings, we consider our results valid. However, pregnancy-related conditions 
and obstetric outcomes were analyzed whenever possible based on dichotomous 
variables in the MBR rather than on ICD-10 diagnoses. 
 
Lastly, when identifying the reasons for preterm deliveries in cancer survivors in 
Study III, our results led us to suspect maternal pregnancy-related conditions 
necessitating medically induced preterm deliveries. However, we could not rule out 
surveillance bias in Studies III and IV, as the obstetricians might be influenced by the 
history of cancer, which might affect their decisions. 
6.7 FUTURE ASPECTS 
    The survival rates are increasing for many cancer types, so it is of great importance 
that possible late effects are taken into account when choosing the cancer therapy. 
Continued research is needed to identify possible changes in occurrence of late 
effects, as new cancer treatments and treatment combinations are constantly being 
introduced. Cancer survivors are especially concerned about late effects on the 
reproductive system. 
 
    We showed that cancer survivors use more fertility treatments than their siblings. 
However, further studies are needed on pregnancy and live birth rates after the 
fertility treatments in cancer survivors. This is important, as reduced pregnancy and 
live birth rates after fertility treatments in cancer survivors would indicate that 
fertility preservation techniques are needed to a larger extent. To acquire more 
information on the indications for the fertility treatments in cancer survivors and 
their siblings, fertility treatment procedure codes could be linked to cancer survivors 
and siblings in addition to their use of fertility drugs. 
 
    Being a cancer survivor was associated with an increased risk for several 
pregnancy-related outcomes, not previously studied. More studies are needed to 
confirm these results. Pregnancy-related cardiotoxicity is a rare condition but 
important to study. In the future, a study linking the hospital discharge register to 
the MBR could be useful when studying this condition. However, pregnancies and 
deliveries in cancer survivors were typically uncomplicated and thus cancer survivors 




This thesis evaluated the reproductive health in female early onset cancer survivors. 
The following conclusions can be made: 
 
1. Female cancer survivors have an increased use of fertility drugs compared to 
siblings, which can be explained by the increased use of assisted reproductive 
technology. Time period of drug purchase played a central role, and an 
increased use of assisted reproductive technology from 2003 onwards was 
observed (Study I).  
 
2. Survivors, diagnosed in their childhood, have the lowest use of fertility 
treatments and seem to become pregnant with less extensive fertility 
treatments than survivors diagnosed as young adults. In cancer survivors 
giving birth, time elapsed from cancer treatment increases the use of fertility 
treatments over time, suggesting that cancer treatments lead to a diminished 
ovarian reserve and a narrowed fertile window (Study II). 
 
3. Cancer survivors have an increased risk for preterm delivery, partially 
explained by certain maternal pregnancy-related conditions (vaginal bleeding 
and pre-eclampsia) that might be more severe in cancer survivors than in 
siblings. Being a cancer survivor is also associated with an increased risk for 
hospitalization during pregnancy and certain maternal pregnancy-related 
conditions (intrahepatic cholestasis, fear of childbirth, use of low molecular 
weight heparin, mental disorders and diseases of the nervous system), 
possibly leading to medically induced preterm delivery. The risk for 
spontaneous preterm delivery (preterm rupture of the amniotic membranes 
and threatened preterm labor) is not increased (Study III). 
 
4. Being a cancer survivor is associated with an increased risk for induction of 
labor and elective cesarean sections. The highest risks for adverse obstetric 
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